The gastrointestinal tract is a unique organ that is constitutively exposed to countless dietary, microbiota-derived and host-derived molecules, including digestive enzymes. Digestive enzymes have essential roles in breaking down dietary macronutrients into smaller components in the upper intestine. However, in the large intestine, they are unneeded and their dysregulated activity has been implicated in changes in microbiota composition, disruption of mucosal barrier integrity and incidence of inflammation 1–3,6,7. To maintain homeostasis and barrier integrity, intestinal tissue implements a variety of regulatory and protective mechanisms, such as the production of mucin and enzyme-inactivating molecules 8–10. Moreover, the gut microbiota contributes substantially to maintaining a stable environment by depleting or modifying luminal materials 11–13. However, it remains unclear how and what microorganisms control digestive enzymes.

Increased levels of proteases, such as trypsin, in the distal intestine have been implicated in intestinal pathological conditions 1–3. However, the players and mechanisms that underlie protease regulation in the intestinal lumen have remained unclear. Here we show that Paraprevotella strains isolated from the faecal microbiome of healthy human donors are potent trypsin-degrading commensals. Mechanistically, Paraprevotella recruit trypsin to the bacterial surface through type IX secretion system-dependent polysaccharide-anchoring proteins to promote trypsin autolysis. Paraprevotella colonization protects IgA from trypsin degradation and enhances the effectiveness of oral vaccines against Citrobacter rodentium. Moreover, Paraprevotella colonization inhibits lethal infection with murine hepatitis virus-2, a mouse coronavirus that is dependent on trypsin and trypsin-like proteases for entry into host cells 6,5. Consistently, carriage of putative genes involved in trypsin degradation in the gut microbiome was associated with reduced severity of diarrhoea in patients with SARS-CoV-2 infection. Thus, trypsin-degrading commensal colonization may contribute to the maintenance of intestinal homeostasis and protection from pathogen infection.

Regulation of trypsin by the microbiota
To examine the influence of the gut microbiota on the landscape of colonic luminal proteins, including digestive enzymes, caecal contents were collected from germ-free (GF) and specific-pathogen-free (SPF) mice and analysed using unbiased mass spectrometry (MS)-based proteomics 14. Out of the 713 host-derived proteins detected (Supplementary Table 1), 324 were found to be higher in SPF mice compared with in GF mice, including immune-related molecules, whereas 45 molecules were more abundant in GF mice than in SPF mice (greater than twofold, $P < 0.05$) (Fig. 1a and Extended Data Fig. 1a), including the mouse anionic isoform of trypsin protease (encoded by Prss2). The marked difference in trypsin levels between GF and SPF mice was confirmed by a trypsin-activity assay, western blotting and immunostaining analysis (Fig. 1b–d). We examined trypsinogen production in the pancreas (Fig. 1e,f) and luminal trypsin activity at different sites of the intestine (Fig. 1g), and differential levels...
ties (Extended Data Fig. 1b,c), suggesting the potential importance of IL10, whereas faecal samples from both humans with inflammatory bowel disease and IIL10-deficient colitogenic mice had higher trypsin activities (Extended Data Fig. 1b,c), suggesting the potential importance of IL10 in the regulation of trypsin in the large intestine.

Trypsin-degrading commensals

Healthy humans and mice tend to have low faecal trypsin levels, whereas faecal samples from both humans with inflammatory bowel disease and IIL10-deficient colitogenic mice had higher trypsin activities (Extended Data Fig. 1b,c), suggesting the potential importance of microorganisms in the large intestine.

of trypsin activity in SPF mice compared with in GF mice (t-test with Welch's correction (nonparametric) (P = 0.0357); ****P < 0.0001, **P < 0.001, *P < 0.05; NS, not significant. For Fig. 1g, scale bar, 500 μm. For c, a representative image from two independent experiments with similar results is shown. For f, images from one experiment including all of the mice used in e are shown. Blot source data are provided in Supplementary Fig. 1.)

Fig. 1 Microbiota-mediated regulation of trypsin in the large intestine.

**a** Proteins with reduced levels in the caecum of SPF mice compared with in the caecum of GF mice, as determined by proteome analysis. **b** Faecal trypsin activity in SPF mice compared with in GF mice. **c** Western blot analysis of trypsin (PRSS2) in the faeces of SPF and GF mice. **d** Immunostaining of colon sections of SPF and GF mice. Blue, DAPI; green, PRSS2; red, UEA1 (mucus).

**e.f.** Prss2 expression levels in the pancreas of SPF or GF mice measured using quantitative PCR with reverse transcription (RT–qPCR) and western blotting (f). Heat-shock protein 90 (HSP90) was the loading control. **g** Trypsin activity of intestinal contents at the indicated locations. **h** Faecal trypsin activity of GF or GF mice inoculated with faecal samples from the indicated healthy donors (A–F). **i** Trypsin activity in faeces of GF mice after inoculation with the caecal contents of mouse C5 and concomitant treatment with antibiotics (Abs) or vehicle control. For **b, e, f, g, h, i**, data are mean ± s.d. Each dot represents one mouse (b, e, g, h, i). Statistical analysis was performed using two-sided Mann–Whitney U-tests with Welch’s correction (nonparametric) (b, e, f, g, h, i) and one-way analysis of variance (ANOVA) with Tukey’s test (b and i). ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05; NS, not significant. For **d, scale bar, 500 μm.** For **c**, a representative image from two independent experiments with similar results is shown. For **f**, images from one experiment including all of the mice used in **e** are shown. Blot source data are provided in Supplementary Fig. 1.
microbial community, the GF + C5 mice were divided into four groups and treated with ampicillin (Amp), metronidazole (MNZ), tylosin (Tyl) or a vehicle control (with no antibiotics) through the drinking water. Faecal trypsin activity was decreased in GF + C5 mice without antibiotic treatment and was further reduced by Amp treatment, whereas treatment with MNZ or Tyl abrogated this reduction (Fig. 1i), suggesting that C5 microbiota contained trypsin-reducing species that were enriched in the Amp-treated group and reduced in the MNZ- and Tyl-treated groups.

We followed up on one of the Amp-treated mice (mouse C5-Amp#5) and cultured its caecal contents in a variety of media under anaerobic conditions (Extended Data Fig. 2a). We picked 432 distinct colonies and analysed them using 16S rRNA gene sequencing to elaborate 35 unique strains that broadly covered the bacterial species colonizing the C5-Amp#5 mouse (Fig. 2a). Introduction of a mixture of the 35 isolated bacteria (35-mix) into GF mice (GF + 35-mix) reproduced the marked decrease in faecal trypsin activity (Fig. 2b). Among the 35 strains, the relative abundances of 14 strains in the faecal microbiota in mice from the aforementioned antibiotic study (Fig. 2a) were negatively associated with trypsin activity (ρ ≤ −0.3) (Extended Data Fig. 2b). The colonization of GF mice with these 14 strains (GF + 14-mix) induced a robust reduction of faecal trypsin, whereas GF mice colonized with the other 21 strains (GF + 21-mix) showed no reduction (Fig. 2c and Extended Data Fig. 2c). A further selection of 9 strains (9-mix) that were significantly associated with a reduction in trypsin activity (ρ ≤ −0.5, P < 0.05) out of the 14-mix similarly reduced trypsin activity (Fig. 2d and Extended Data Fig. 2c). We next divided the 9-mix into a 3-mix consisting of Bacteroidales species and a 6-mix consisting of non-Bacteroidales species. The 3-mix was sufficient to decrease faecal trypsin activity (Fig. 2e and Extended Data Fig. 2c). In vitro incubation of the individual strains of the 9-mix with recombinant mouse trypsin (rmPRSS2, with a C-terminal His-tag) revealed that Paraprevotella clara (strain ID: 1C4) was the only strain with the ability to reduce the amount of trypsin (Fig. 2f). Consistently, GF mice colonized with the 3-mix (excluding P. clara from the 3-mix) or the 34-mix (excluding P. clara from the 35-mix) showed defects in reducing trypsin activity (Fig. 2g,h), confirming that P. clara is the effector strain out of the 35-mix.

The small fragment recognized by the anti-His-tag antibody indicates trypsin degradation by P. clara (Fig. 2f,j). Degradation also occurred when P. clara was incubated with the three known isoforms of human trypsin (PRSS1 and PRSS2 and, to a lesser extent, PRSS3) (Fig. 2i). Paraprevotella clara is a recently identified genus under the family Prevotellaceae, containing only two species, P. clara and Paraprevotella xylaniphila. We examined several P. clara and P. xylaniphila strains, as well as species from the phylogenetically related Prevotella genus, and we found that the trypsin-degrading property is conserved in all Paraprevotella strains but is absent in the tested Prevotella strains (Fig. 2j).

Molecules involved in trypsin degradation
Ex vivo incubation of GF caecal contents with P. clara showed a gradual loss of trypsin and an increase in trypsin-derived peptides (Extended Data Fig. 3a–c). The liquid chromatography coupled with MS (LC–MS)-based peptidome analysis revealed no P. clara substrates other than trypsin (Extended Data Fig. 3a and Supplementary Table 2). P. clara-mediated trypsin degradation occurred only in the presence of divalent cations (such as Ca²⁺) (Extended Data Fig. 3d). Thus, the degradation appears to be enzyme (protease) mediated. However, P. clara culture supernatant did not degrade trypsin (Extended Data Fig. 3e), and no proteolytic activity was detected in live P. clara or in the supernatant (Extended Data Fig. 3f). Instead, pretreatment of trypsin with trypsin inhibitors (AEBSF, leupeptin and TLCK) inhibited its degradation by P. clara (Fig. 3a), suggesting that the degradation is mediated by trypsin-dependent autolysis. Moreover, fluorescently labelled trypsin was found to accumulate on the surface of P. clara (Fig. 3b). Thus, trypsin degradation probably occurs on the surface of P. clara through trypsin-binding surface molecules that facilitate trypsin accumulation and autolysis.

We used disuccinimidyl sulfoxide (DSSO), a chemical cross-linker, to examine molecules on P. clara that interact with His-tagged trypsin. DSSO treatment resulted in the emergence of a new band with a high molecular mass (around 250 kDa) blotted by an anti-His-tag antibody, indicative of a trypsin-containing complex (Extended Data Fig. 3g). The smeared appearance of the band suggests that trypsin interacts with molecules that are heterogenous in size. Bacteroidetes (in which Paraprevotellaclara is included) are known to decorate their cell surface with complex glycans. We therefore used inhibitors to target glycan synthesis in P. clara, reasoning that glycan-binding molecules are possible trypsin-binding partners. P. clara pretreated with tunicamycin, which inhibits synthesis of lipopolysaccharide (LPS) O-glycans, showed defects in the recruitment and degradation of trypsin (Fig. 3c,d). Similar results were obtained when P. clara was treated with 2-fluro-L-fucose, which broadly inhibits the synthesis of fucose-containing glycans (Extended Data Fig. 4a,b). Treatment with tunicamycin led to a loss of glycan-containing proteins from the cell lysate (Extended Data Fig. 4c) and elevated protein shedding into the supernatant (Extended Data Fig. 4d). This was reminiscent of what was reported for LPS-deficient Porphyromonas gingivalis mutants, which were unable to anchor type IX secretion system (T9SS)-dependent outer membrane proteins (for example, gingipains) to LPS on the surface. The T9SS is a bacterial machinery that transports proteins bearing a conserved C-terminal domain (CTD) across the outer membrane to the surface, removes the CTD and mediates the attachment of the exported proteins to surface polysaccharides. Putative T9SS genes were identified in the genomes of Paraprevotellaclara (Extended Data Fig. 5a). We therefore hypothesized that surface proteins secreted by the T9SS might be responsible for the recruitment and degradation of trypsin. To test this, we generated a mutant P. clara deficient for PorU (an essential component of the T9SS) by inserting a plasmid sequence into the gene locus (Extended Data Fig. 5b). Disruption of PorU led to a complete defect in trypsin degradation (Fig. 3e).

We next conducted a proteome analysis of P. clara culture supernatants in the presence or absence of tunicamycin and found 20 bacterial proteins that were significantly elevated in the supernatant of tunicamycin-treated P. clara (Fig. 3f). Thus, we generated a series of mutant P. clara strains disrupting the synthesis of these tunicamycin-sensitive proteins by insertional mutagenesis (Extended Data Fig. 5b) or by deletion of a gene cluster (Δ00508-03053) (Extended Data Fig. 6a). Disruption of the gene encoding PROKKA_00502 (Omp28-related outer membrane protein) or PROKKA_00509 (hypothetical protein) resulted in the abrogation of trypsin degradation in vitro, similar to in PorU-deficient or Weca-deficient (target of tunicamycin) mutants (Fig. 3g). In addition to insertional mutants, we generated P. clara deletion mutants for 00502 and 00509 (∆00502 and ∆00509) (Extended Data Fig. 6a), and both strains showed severe defects in the recruitment and degradation of trypsin (Extended Data Fig. 6b). Mutants defective in PorU, Weca, 00502 and 00509 displayed no growth defects (Extended Data Fig. 6c), indicating that trypsin degradation is not essential for in vitro bacterial growth. The 00502-00509 locus is conserved in all tested Paraprevotella strains (Extended Data Fig. 6d). However, the 00503-00508 genes separating 00502 and 00509 were not required for trypsin degradation (Extended Data Figs. 5b and 6e).

We next generated recombinant 00502 and 00509 proteins (Extended Data Fig. 7a,b). No protease activity was detected for the recombinant proteins (Extended Data Fig. 7c), and free-form 00502 or 00509 did not degrade trypsin (Fig. 3j). Coupling recombinant 00502 to microbeads enabled effective recruitment and in vitro degradation of recombinant trypsin (Fig. 3j), as well as ex vivo degradation of trypsin in GF caecal contents (Extended Data Fig. 7d). 00509-coupled beads facilitated trypsin recruitment but not degradation (Fig. 3j).
Paraprevotella or Prevotella strains (J), and degradation of rmPRSS2 was analysed using western blotting. The asterisk indicates the cleaved fragment of rmPRSS2. I. Recombinant human trypsin isoforms PRSS1, PRSS2 and PRSS3 (rhPRSS1–3) were incubated with P. clara IC4 and degradation of human trypsin was analysed using western blotting. For b–e, g and h, data are mean ± s.d. Each dot represents one mouse. Statistical analysis was performed using two-sided Mann–Whitney U-tests with Welch’s correction (nonparametric) (h) and one-way ANOVA with Tukey’s test (b,e and g). ****P < 0.0001, **P < 0.001, *P < 0.01. For f, i and j, representative images from two independent experiments with similar results are shown. Blot source data are provided in Supplementary Fig. 1.

Recombinant 00502 showed two distinct bands on a native PAGE gel: one corresponds to the monomer form and the other probably corresponds to oligomers (Extended Data Fig. 7e). After incubation

results suggest that 00502 functions as a core effector component for trypsin recruitment and autodegradation, whereas 00509 probably has a supporting role in facilitating trypsin recruitment.
Fig. 3 | Identification of effector molecules responsible for Paraprevotella-mediated trypsin degradation. a, Recombinant mouse trypsin (rmPRSS2) pretreated with the indicated protease inhibitors was incubated with P. clara 1C4, and degradation of rmPRSS2 was analysed using western blotting. b, Alexa Fluor 488-labelled rmPRSS2 (green) was incubated with the indicated species, and association of rmPRSS2 with the bacterial surface was examined using confocal microscopy. The black square indicates the region magnified in the top right, showing P. clara cells. c, d, rmPRSS2 degradation (c) and association with the bacterial surface (d) after incubation with P. clara 1C4 pretreated with tunicamycin or vehicle control. e, f, rmPRSS2 degradation mediated by WT or PorU mutant P. clara JCM14859. i, Transmission electron microscopy images of WT or Δ00502 strains incubated with rmPRSS2. The green arrowheads indicate immuno-gold labelled rmPRSS2. j, rmPRSS2 degradation after incubation with microbead-coupled or free-form recombinant 00502 and/or 00509. k, Association of rmPRSS2 with microbead-coupled recombinant 00502 and/or 00509 or albumin control (BSA). For f, k, data are mean ± s.d. Each dot represents one technical replicate. Statistical analysis was performed using two-sided multiple unpaired t-tests (not corrected for multiple comparisons); ***P < 0.0001, **P < 0.001, *P < 0.01, P < 0.05. Scale bars, 5 μm (b, d, h and k) and 200 nm (f). For a–e and g–k, representative images from two independent experiments with similar results (a–e, g, h, j and k) or images from one experiment (b) are shown. Blot source data are provided in Supplementary Fig. 1.

with trypsin, both bands shifted upwards (Extended Data Fig. 7f), suggesting that trypsin forms complexes with either form of 00502. Western blot analysis (Extended Data Fig. 7f) and in-gel MS/MS analysis (Supplementary Table 3) confirmed recovery of both 00502 and trypsin from these bands. We found no bands indicative of oligomer or complex formation for 00509 on a native PAGE gel (Extended Data Fig. 7g). These data suggest that 00502 tends to oligomerize, and oligomerized 00502 possibly brings multiple trypsin molecules together to facilitate autolysis (Extended Data Fig. 8a). We predicted the structure of 00502s from P. clara and P. xylaniphila using AlphaFold2. The resulting model is composed of an N-terminal WD40 domain with five immunoglobulin (Ig) like domains (Extended Data Fig. 8b, c). These Ig-like domains are well conserved among 00502 proteins of Paraprevotella species and could be binding sites for trypsin. The Ig-like domain at the C-terminus aligns well with CTD of the gingipain RgpB, a known T9SS target (Extended Data Fig. 8g).
**P. clara** maintains IgA

To confirm the contribution of 00502 and 00509 to trypsin degradation in vivo, we inoculated GF mice with the wild-type (WT), Δ00502 or Δ00509 P. clara JCM14859 strain together with two trypsin non-degrading strains (2-mix; Fig. 2g) (notably, *P. clara* was unable to monoclonize mice). *P. clara* strains equally colonized the mouse intestine in combination with the 2-mix (Extended Data Fig. 9a–c). Consistent with our in vitro findings, mice colonized with Δ00502 *P. clara* retained high faecal trypsin levels, whereas mice colonized with Δ00509 *P. clara* showed a partial reduction in trypsin (Fig. 4a,b). Even in the presence of a more complex microbiota community (34-mix, see Fig. 2h), WT *P. clara* reduced faecal trypsin activity, whereas Δ00502 *P. clara* did not do so (Fig. 4c). Notably, under this relatively competitive condition, although the overall bacterial load or composition of the 34-mix strains showed little difference, WT *P. clara* colonized more abundantly than Δ00502 *P. clara* (Extended Data Fig. 9a,b,d). Moreover, when the two *P. clara* (WT and Δ00502) strains were co-administered to GF+2-mix mice, the WT strain colonized more effectively and eventually outcompeted the Δ00502 strain (Extended Data Fig. 9e–g). These data suggest that 00502 has an essential role in facilitating trypsin degradation in vivo, and that the ability of trypsin degradation confers the bacterium with a colonization advantage under competitive conditions.

We next addressed the relevance of trypsin activity regulation in vivo. We examined its effects on immune molecules and found that mice colonized with WT *P. clara* had considerably higher levels of faecal IgA heavy chain (α chain) compared with mice colonized with Δ00502 or Δ00509 *P. clara*, whereas the κ light chain and the antimicrobial peptide Reg3β showed little difference (Fig. 4b). Ex vivo incubation of faeces from GF+2-mix+WT *P. clara* mice (containing high IgA) with faeces from GF mice (containing high trypsin), or with recombinant trypsin, confirmed that the α chain is indeed trypsin sensitive (Extended Data Fig. 10a). These data suggest that *P. clara* colonization protects IgA, particularly the heavy chain, from proteolytic cleavage by trypsin in vivo.

Reasoning that *P. clara*-mediated trypsin degradation and the consequent protection of IgA might enhance the effectiveness of oral vaccines against enteropathogens, we used a vaccination model with *C. rodentium*, which is an intestinal pathogen and a model for enteropathogens, we used a vaccination model with *C. rodentium* (Extended Data Fig. 10c). Caecal suspension from WT *C. rodentium* showed less reduction in body weight (Extended Data Fig. 10c), lower *C. rodentium* shedding (Extended Data Fig. 10f), and prolonged survival (Fig. 4e). MHV-2-induced necrotic liver pathology was less severe in mice colonized with WT *P. clara* (Fig. 4f). Similar observations were made in the context of a complex microbiota, that is, GF+34-mix+WT *P. clara* mice tended to be more resistant to MHV-2 infection compared with GF+34-mix+Δ00502 *P. clara* mice (Fig. 4g,h). Notably, when MHV-2 was applied through the intraperitoneal route, there was no difference in survival between WT *P. clara*-colonized and Δ00502 *P. clara*-colonized groups (Fig. 4i). Although further studies are required, these data suggest that *P. clara* 00502 gene carriage and consequent protease degradation provide protective benefits to the host against MHV-2 infection through the intestinal route.

### 00502 homologues in the human microbiome

We analysed the abundance and prevalence of 00502 and 00509 homologue genes by mining a de novo assembled human gut microbiome gene catalogue from 6 geographically diverse cohorts consisting of about 6 million non-redundant complete genes. We first detected *P. clara*, *P. xylaniphila* and two additional metagenomic species (MSP0303 and MSP0335) that have a conserved gene cluster with 00502-00509 homologues and potentially fall within the genus *Paraprevotella* (Fig. 4j and Extended Data Fig. 11a). We identified five additional Bacteroidetes metagenomic species (MSP0081 (*Prevotella rara*), MSP0224 (*Prevotellamassiliatimonensis*), MSP0288, MSP0410 and MSP0435) that have 00502 and 00509 homologues only (Fig. 4j). These 00502-00509-processing species showed, on average, a relative abundance of up to 9% (Extended Data Fig. 11b). Their prevalence varied greatly across the different cohorts, with *P. clara* being the most prevalent 00502 encoder (Extended Data Fig. 11c). We also mined a publicly available mouse metagenomic database and found 00502 homologues in the genomes of *Prevotellatardata* and *Prevotellamuris* (Fig. 4j). We obtained isolates of *P. rara*, *P. rodentium* and *P. muris*, and confirmed that all three isolates could facilitate trypsin degradation (Extended Data Fig. 12a). Thus, the presence of 00502 correlated well with the ability of a species to degrade trypsin. *P. rodentium* was detected in the faeces of the SPF mice reared in our facility (Extended Data Fig. 12b), possibly contributing to the low trypsin levels in these mice (Fig. 1g). All of the trypsin-degrading strains recruited fluorescently labelled trypsin to the surface (Extended Data Fig. 12c). The similarity of the predicted structures of all 00502 homologues suggests a common mechanism used by these species (Extended Data Fig. 8b–f).

### 00502 homologues and COVID-19 diarrhoea

Finally, we recruited 146 individuals who were diagnosed with COVID-19 and hospitalized at the Keio University hospital. Faecal samples were collected from the participants after discharge from the hospital and were processed for metagenome sequencing. We examined the association between the carriage of 00502 homologue genes in the gut microbiome and the disease severity and diarrhoea frequency (information of diarrhoea incidence along with the Bristol stool form scale (BSFS) during hospital care was available for 141 cases from medical records (Supplementary Table 4). A total of 62 (44%) out of the 141 participants experienced diarrhoea (BSFS 5–7) during hospitalization. We found
**Fig. 4 | Paraprevotella-mediated degradation of trypsin modulates colonic homeostasis.** a–c, GF mice were colonized with the indicated *P. clara* strains together with the 2-mix (a, n = 5 mice per group) or the 34-mix (c, n = 6 mice per group) for 14 days. Faecal trypsin activity (a, e) and the amount of indicated proteins (b, determined by western blotting) are shown. d–f, The viral RNA levels in the faeces or the indicated tissues (d), survival curve (e) and representative images of haematoxylin and eosin (H&E) staining of liver sections (f) of GF+2-mix+WT or GF+2-mix+Δ00502 mice infected with MHV-2 (intragastric inoculation). Among the 32 (GF+2 mix+WT group) and 33 (GF+2 mix+Δ00502 group) infected mice, 16 mice from each group were euthanized on day 5 for tissue viral RNA analysis (d) and the rest of the mice were followed for survival analysis (e, g, h). Viral RNA levels (g) and survival curve (h) of GF+34-mix+WT or GF+34-mix+Δ00502 mice after intragastric inoculation with MHV-2, n = 15 mice per group (10 mice were euthanized on day 5 for tissue viral RNA analysis and the rest of the mice were followed for survival analysis). i, Survival curve of GF+2-mix+WT or GF+2-mix+Δ00502 mice intraperitoneally injected with MHV-2, n = 5 mice per group. j, Genome neighbourhood of the homologues of the *P. clara* 00502-00509 locus in human and mouse (*P. rodentium* and *P. muris*) gut microorganisms. The percentage amino acid identity with *P. clara* 00502 and 00509 is shown. k, l, The frequency of patients with COVID-19 experiencing more than 1 day with more than 2 diarrhoeal episodes per day (k) or requiring oxygen inhalation therapy (l), stratified by the presence (00502 (+)) or absence (00502 (−)) of 00502 homologue genes in the faecal metagenome. For a, c, d and g, data are mean ± s.d. Each dot represents one mouse. Statistical analysis was performed using one-way ANOVA with Tukey’s test (a), two-sided Mann–Whitney U tests with Welch’s correction (nonparametric) (c, d and g), log rank (Mantel–Cox) tests (e, h and i) and one-sided Fisher’s tests (k and l); ***P < 0.0001, **P < 0.001, *P < 0.01, *P < 0.05. For f, scale bar, 500 μm. For b, images from one experiment, including all of the mice used in a, are shown. Blot source data are provided in Supplementary Fig. 1.
that the incidence of severe diarrhoeal episodes (more than twice per day lasting for more than 1 day) was significantly more frequent in participants who were negative for 00502 homologues (P = 0.035, one-sided Fisher’s test) (Fig. 4k). Moreover, the absence of 00502 homologues in the gut microbiome was significantly associated with a higher rate of oxygen inhalation (P = 0.049, one-sided Fisher’s test) (Fig. 4l). Although further studies are required, these results are consistent with our hypothesis that trypsin-degrading commensal colonization may provide protective benefits against SARS-CoV-2 infection.

Discussion

Here we identified gut commensals that effectively degrade trypsin in the large intestine. Mechanistically, the degradation is mediated by the T9SS-dependent, polysaccharide-binding outer membrane proteins 00502 and 00509. We show that 00502 is absolutely essential for trypsin recruitment and autodegradation by Paraprevotella, and that the autodegradation is possibly facilitated by 00502 oligomerization (Extended Data Fig. 8a). Degradation of trypsin probably increases the fitness of trypsin-degrading species in a competitive environment. Moreover, trypsin affects intestinal IgA levels and responses to previously encountered enteropathogens. Carriage of the 00502 gene was associated with resistance to MHV-2 infection in mice and reduced diarrhoea severity during COVID-19 in humans, suggesting that 00502-mediated trypsin degradation potentially affects host sensitivity to intestinal viral infections. There are a number of limitations to our metagenome analysis of our COVID-19 cohort. In particular, owing to the small number of participants, the data were unadjusted for known confounders such as age, sex and comorbidities. The causal relationship between trypsin degradation and the protection against SARS-CoV2 infection needs to be further validated by larger cohorts and additional animal models. Nevertheless, our study provides valuable insights into the mechanisms and physiological implications of microbiota-mediated protease regulation. Moving forwards, we could take advantage of the unique trypsin-degrading ability of the identified bacteria and molecules to treat or prevent infectious diseases.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-022-05181-3.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide the link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022
**Methods**

**Mice**

C57BL/6 mice maintained under SPF or GF conditions were purchased from Sankyo Laboratories Japan, SLC Japan, Charles River Japan or CLEA Japan. Gnotobiotic mice were maintained within the gnotobiotic facility of RIKEN IMS. SPF and GF WT male and female mice (aged 8–12 weeks) were used in this study. Sex-matched littersmates were used in all of the experiments. All of the animals were maintained under a 12 h–12 h light–dark cycle and received gamma-irradiated (50 kGy) pellet food (CMF, Oriental Yeast). A temperature of 20–24 °C and a humidity of 40–60% were used for the housing conditions. All of the animal experiments were approved by the Animal Care and Use Committee of RIKEN Yokohama Institute.

**Collection of human faecal samples for trypsin-activity assays and for colonization of GF mice with human microbiota**

Human faecal samples were collected at the RIKEN Institute (code H30-0, for patients with inflammatory bowel disease) and Keio University (code 20150073, for healthy donors) according to the study protocols approved by the institutional review boards. Informed consent was obtained from each participant.

**Bacterial strains**

P. xylaniphila JCM14859, P. clara P237E3b and P322B5 strains were obtained from the Japan Collection. Prevotella copri JCM14860, Prevotella denticola JCM13449, Prevotella stercorea JCM13469 and Prevotella oulorum JCM14966 were acquired from the Japan Collection of Microorganisms (JCM). P. clara P237E3b and P322B5 strains were derived from Vedanta Biosciences. P. xylaniphila 82A6 was a strain isolated at the Honda laboratory. P. rara (DSM 105141), P. rodentium (DSM 105243) and P. muris (DSM 103722) were obtained from the DSMZ-German collection of Microorganisms and Cell Cultures. Bacterial strains are available under a contract with material transfer agreement with RIKEN.

**Proteome analysis of caecal contents**

Proteins in caecal contents were extracted by pipetting and inverting in TBST with protease inhibitors. After centrifugation at 15,000 g for 20 min at 4 °C to remove insoluble matter, the supernatant was transferred to a new tube, 25% trichloroacetic acid was added (final concentration 12.5% v/v) and incubated for 1 h at 4 °C. After removing the supernatant by centrifugation at 15,000 g for 15 min at 4 °C, the precipitate was washed twice with acetone and dried with the lid open. The dried sample was redissolved in 0.5% sodium dodecanoate and 100 mM Tris-HCl, pH 8.5 by using a water-bath-type sonicator (Bioruptor UCD-200). The redissolved sample was assayed for protein concentration using the BCA assay and the protein concentration was adjusted to 1 μg μl⁻¹. The pretreatment for shotgun proteome analysis was performed as previously reported. Peptides were directly injected onto a 75 μm × 15 cm, PicoFrit emitter packed in house with 2.7 μm core shell C18 particles at 30,000 resolution to set an automatic gain control (AGC) target of 3 × 10⁵ and a maximum injection time of 55. MS2 spectra were collected in the range of more than 200 m/z at 30,000 resolution to set an AGC target of 3 × 10⁵, maximum injection time of ‘auto’ and stepped normalized collision energy of 22, 26 and 30 %. An isolation width for MS2 was set to 4 m/z and overlapping window patterns in 500–700 m/z were used window placements optimized by Skyline.

MS files were searched against a P. clara spectral library using Scaffold DIA (Proteome Software). The spectral library was generated from P. clara protein sequence databases by Prosi43,44. The P. clara protein sequence database was independently created by metagenomic analysis. The Scaffold DIA search parameters were as follows: experimental data search enzyme, trypsin; maximum missed cleavage sites, 1; precursor mass tolerance, 8 ppm; fragment mass tolerance, 8 ppm; static modification, cysteine carbamidomethylation. The protein identification threshold was set with both peptide and protein false-discovery rates of less than 1%. Peptide quantification was calculated using the EncyclopeDIA algorithm in Scaffold DIA. For each peptide, the four highest-quality fragment ions were selected for quantification. Protein quantification was estimated from the summed peptide quantification.

**Peptidome analysis**

To the caecal contents, acetonitrile containing 0.1% TFA was added and dried in a centrifugal evaporator. Acetonitrile was added to the dried sample and lipid-soluble small molecules were extracted with a water-bath-type sonicator, followed by centrifugation at 15,000 g for 15 min at 4 °C. After the supernatant was removed, 70% acetonitrile-12 mM HCl was added to the precipitate and the peptide was redissolved by a water-bath-type sonicator, followed by centrifugation at 15,000 g for 15 min at 4 °C. The supernatant was transferred to a new tube and dried in a centrifugal evaporator. The dried sample was redissolved in 100 mM Tris-HCl and protease inhibitors, and treated with 10 mM diithiothreitol at 50 °C for 30 min. Subsequently, the sample was alkylated with 30 mM cysteine carbamidomethylation. The protein identification threshold was set with both peptide and protein false-discovery rates of less than 1%. Peptide quantification was calculated using the EncyclopeDIA algorithm in Scaffold DIA. For each peptide, the four highest-quality fragment ions were selected for quantification. Protein quantification was estimated from the summed peptide quantification.

**Proteome analysis of P. clara culture supernatant**

Trichloroacetic acid (25%; final concentration 12.5% v/v) was added to the P. clara culture supernatant and incubated for 1 h at 4 °C. After removing the supernatant by centrifugation at 15,000 g for 15 min at 4 °C, the precipitate was washed twice with acetone and dried with the lid open. The dried sample was redissolved in 0.5% sodium dodecanoate and 100 mM Tris-HCl, pH 8.5 by using a water-bath-type sonicator (Bioruptor UCD-200). The redissolved sample was assayed for protein concentration using the BCA assay, and the protein concentration was adjusted to 1 μg μl⁻¹. The pretreatment for shotgun proteome analysis was performed as previously reported. Peptides were directly injected onto a 75 μm × 20 cm PicoFrit emitter packed in house with 2.7 μm core shell C18 particles at 50 °C and then separated with an 80 min gradient at a flow rate of 100 nl min⁻¹ using the UltiMate 3000 RSLCnano LC system (Thermo Fisher Scientific). Peptides eluting from the column were analysed using the Q Exactive HF-X (Thermo Fisher Scientific) system for overlapping window DIA-MS⁴¹,⁴⁴. MS1 spectra were collected in the range of 495–785 m/z at 30,000 resolution to set an automatic gain control (AGC) target of 3 × 10⁶ and a maximum injection time of 55. MS2 spectra were collected in the range of more than 200 m/z at 30,000 resolution to set an AGC target of 3 × 10⁵, maximum injection time of ‘auto’ and stepped normalized collision energy of 22, 26 and 30 %. An isolation width for MS2 was set to 4 m/z and overlapping window patterns in 500–780 m/z were used window placements optimized by Skyline.

MS files were searched against a P. clara spectral library using Scaffold DIA (Proteome Software). The spectral library was generated from P. clara protein sequence databases by Prosi43,44. The P. clara protein sequence database was independently created by metagenomic analysis. The Scaffold DIA search parameters were as follows: experimental data search enzyme, trypsin; maximum missed cleavage sites, 1; precursor mass tolerance, 8 ppm; fragment mass tolerance, 8 ppm; static modification, cysteine carbamidomethylation. The protein identification threshold was set with both peptide and protein false-discovery rates of less than 1%. Peptide quantification was calculated using the EncyclopeDIA algorithm in Scaffold DIA. For each peptide, the four highest-quality fragment ions were selected for quantification. Protein quantification was estimated from the summed peptide quantification.
iodoacetamide in the dark at room temperature for 30 min and acidified with 0.5% trifluoroacetic acid (final concentration). The acidified sample was desalted by Monospin C18 (GL Sciences).

Peptides were directly injected onto a 75 μm × 25 cm PicoFrit emitter (New Objective) packed in-house with C18 core-shell particles (CAP-CELL CORE MP 2.7 μm, 160 Å material; Osaka Soda) at 50 °C and then separated with a 90 min gradient at a flow rate of 100 nl min⁻¹ using an UltiMate 3000 RSLC nano LC system (Thermo Fisher Scientific). Peptides eluting from the column were analysed using the Q Exactive HF-X (Thermo Fisher Scientific) for DDA-MS. MSI spectra were collected in the range of 380 to 1,500 m/z with 120,000 resolution to hit an AGC target of 3 × 10⁶. The 30 most intense ions with charge states of 2⁺ to 8⁺ that exceeded 4 × 10⁴ were fragmented in data-dependent mode by collision-induced dissociation with stepped normalized collision energy of 21%, 25% and 29%, and tandem mass spectra were acquired on the Orbitrap mass analyser with a mass resolution of 30,000 at 200 m/z to set an AGC target of 2 × 10⁵.

MS files were searched against the mouse UniProt protein sequence database (UP000000589; reviewed, canonical) by PEAKS Studio. The search parameters were as follows: precursor mass tolerance, 8 ppm; fragment ion mass tolerance, 0.01 Da; enzyme, no enzyme; fixed modifications, carbamidomethylation; variable modifications, oxidation (M). The peptide identification was filtered to a peptide false discovery rate of less than 1%.

### In-gel digestion and LC–MS/MS analysis

The protein bands were excised, and in-gel digestion was performed as previously described. The digested peptides were directly injected onto a 75 μm × 12 cm PicoFrit emitter (New Objective) at 40 °C and then separated with a 30 min gradient at a flow rate of 200 nl min⁻¹ using the UltiMate 3000 RSLCnano LC system (Thermo Fisher Scientific). Peptides eluted from the column were analysed on the Q Exactive Fast-HF (Thermo Fisher Scientific) system for DDA-MS. MSI spectra were collected in the range of 380 to 1,240 m/z with 120,000 resolution to hit an AGC target of 3 × 10⁵. The 20 most intense ions with charge states of 2⁺ to 5⁺ were data-dependently dissociated by collision-induced dissociation with step-normalized collision energies of 22%, 26%, 30% and 30%, and tandem mass spectra were acquired on the Orbitrap mass analyser with 30,000 resolution to set an AGC target of 1 × 10⁵.

MS files were searched against the *P. clara* protein sequence database with human PRSS2 sequence (UniProt: P07478) using PEAKS Studio. The search parameters were as follows: precursor mass tolerance, 8 ppm; fragment ion mass tolerance, 0.01 Da; enzyme, trypsin; variable modifications, oxidation (M). Peptide and protein identifications were filtered so that both peptide and protein false discovery rates were less than 1%.

### Western blot analysis

Mouse caecal and faecal samples were suspended and diluted 50-fold in PBS supplemented with a protease inhibitor cocktail (Roche cOmplete, Mini, EDTA-free). Resuspended samples were centrifuged at 4 °C, 15,000g for 10 min, and the supernatant was collected for western blotting. Mouse pancreatic tissues were snap-frozen in liquid nitrogen at 4 °C overnight. A tissue processor (Leica Microsystems) was used for paraffin embedding. Paraffin blocks were cut into 4 μm sections, deparaffinized with Cornoy solution (60% methanol, 30% chloroform, 10% glacial acetic acid) at 4 °C overnight. The Leica AF600 and confocal Leica TCS SP5 systems were used for imaging. Full scans of all of the blots are provided in Supplementary Fig. 1.

### RT-qPCR

RNA from mouse pancreas, small intestine and colon organoids was extracted by TRIzol Reagent (Thermo Fisher Scientific). Extracted RNA was converted to cDNA using the ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO). RT–qPCR analysis was conducted with the Thunderbird SYBR qPCR Mix (Toyobo) and Lightcycler480 v.1.5.1 (Roche) software and analysed using the ΔΔCt method or using a standard curve generated from serial dilutions of pooled cDNA (for *Tmprss2, Ceacam1* and *Actb*). *Gapdh* and *Actb* were used as the endogenous control. Primer sequences were as follows: for *Gapdh* forward primer, 5′-GTCGTTGAGTCTACTGGTGTCTTC-3′; *Gapdh* reverse primer, 5′-GTCATAATTTCGTCGTTGTCACCC-3′; for *Tmprss2* forward primer, 5′-TGTTGACCTCTCAATGGCACAG-3′; *Tmprss2* reverse primer, 5′-AGCAGTGGCCAGTCAACAC-3′; for *Ceacam1* forward primer, 5′-AAGCGAAAGCCTCAACATCTG-3′; *Ceacam1* reverse primer, 5′-AAGCTCAAAAGCAACAGC-3′; for *Actb* forward primer, 5′-GGTGTGGAGTCTACTGGTGTCTTC-3′; *Actb* reverse primer, 5′-TTTACTGACAGATGCGAAG-3′; for *Gapdh* forward primer, 5′-GTCATAATTTCGTCGTTGTCACCC-3′; *Gapdh* reverse primer, 5′-ATCCATCTGCTGGAAATGGT-3′.

### Immunofluorescence

Mouse colon tissues (containing faecal pellet) were sampled and fixed with Carnoy solution (60% methanol, 30% chloroform, 10% glacial acetic acid) at 4 °C overnight. A tissue processor (Leica Microsystems) was used for paraffin embedding. Paraffin blocks were cut into thin sections (5.0 μm) using a microtome, followed by paraffin removal and immunostaining. The antibodies and stains used for immunofluorescence were as follows: rabbit anti-PRSS2 (LSBio, LS-C296077, 1:100), Alexa 488-labelled goat anti-rabbit IgG (Thermo Fisher Scientific, A10080, 1:1000), 4′-6-diamidino-2-phenylindole (DAPI, DOJINDO), rhodamine-labelled UEA1 (Europaeus Agglutinin I, Vector Laboratories). The Leica AF600 and confocal Leica TCS SP5 systems were used for immunofluorescence imaging.

### Trypsin-activity assay of mouse and human faecal samples

Mouse intestinal luminal contents or faecal samples were diluted 500-fold (w/v) in 0.9% NaCl solution. Human faecal samples were diluted 200-fold (w/v) in 0.9% NaCl solution. The diluted solutions were vortexed with a mini-shaker for 20 min at 2,000 rpm, homogenized by pipetting and centrifuged at 4 °C for 10,000 g for 15 min. The supernatant was collected for trypsin-activity assay using the Trypsin Activity Assay Kit (Colorimetric) (ab102531) according to the manufacturer’s protocol. Absorbance at 405 nm was measured using the PerkinElmer 2030 Multilabel Reader in kinetic mode.
Colonization of GF mice with human microbiota

Human faecal samples (preserved in 20% (v/v) glycerol) were transferred to an anaerobic chamber, thawed and sieved through 100 μm meshes, transferred into a GF isolator and introduced into GF mice by oral gavage (200 μl per mouse). For antibiotics treatment, 0.5 g l⁻¹ ampicillin (nalacal tissue), 0.5 g l⁻¹ metronidazole (nalacal tissue) and 1.0 g l⁻¹ tylosin (Sigma-Aldrich) solutions were made using autoclaved tap water. Mice receiving oral gavage of the caecal contents from the donor-C-microbiota-colonized mouse were fed with antibiotic solutions for 12 days. Antibiotic solutions were replaced once per week.

Isolation and identification of colonized species from mouse caecal contents

Mouse caecal contents were mixed with glycerol-containing (20%) PBS in an anaerobic chamber and stocked at −80 °C. An aliquot was diluted with TS broth (BD) in an anaerobic chamber and plated onto different agar plates: EG, ES, NBGT, VS, TS (BD), BL (Eiken Chemical), BBE (Kyokuto Seiyaku), Oxoid CM0619 (Thermo Fisher Scientific), CM0619-supplemented SR0107 (Thermo Fisher Scientific), CM0619-supplemented SR0108 (Thermo Fisher Scientific), mGAM (NISSUI-Pharm) and Schaelder (BD). After incubation for 2 days, colonies with different appearances were transferred to new EG plates. Colonies were then incubated in EGEF liquid medium overnight, mixed with glycerol (final concentration 20% (v/v)) and stocked at −80 °C.

The formula of EG (Eggerth Gagnon) agar plates is as follows: protease peptone no. 3 (10.0 g), yeast extract (5.0 g), Na 2HPO4 (4.0 g), K 2HPO4 (1.0 g), glucose (1.5 g), soluble starch (0.5 g), l-cysteine HCl (0.5 g), l-cystine (0.2 g), Tween-80 (0.5 g), agar (4.8 g), horse meat extract (500 ml), water up to 1,000 ml + defibrinated horse blood (50 ml). EGEF medium was the same, except with no agar and defibrinated horse blood (50 ml) was replaced with Fildes solution (40 ml).

The bacterial DNA genome was extracted from the isolated strains using the same protocol as DNA isolation from faecal samples (below). 16S rRNA was amplified by PCR using the KOD plus Neo (TOYOBO) kit according to the manufacturer’s protocol. Sanger sequencing was performed by Eurofins. Sequences were blasted against NCBI database. Primers for Sanger sequencing were as follows: F27 primer, 5’-AATGATACGGCGACCACCGAGATCTACACTCTTCTATGGGCTCAG-3′; R1492 primer, 5’-TCAGGGTTATCCTGTAGTGACCT-3′.

16S rRNA sequencing

Frozen mouse faecal samples were thawed and 100 μl of the suspensions was mixed with 900 μl TE10 (10 mM Tris-HCl, 10 mM EDTA) buffer containing RNase A (final concentration 100 μg ml⁻¹), Invertin, and lysozyme (final concentration 3.0 mg ml⁻¹, Sigma-Aldrich). The suspension was incubated for 1 h at 37 °C with gentle mixing. Purified chromopeptidase (Wako) was added to a final concentration 1% and the sample was further incubated for 30 min at 37 °C. Sodium dodecyl sulfate (final concentration 1%) and protease K (final concentration 1 mg ml⁻¹, Nacala) were then added to the suspension and the mixture was incubated for 1 h at 55 °C. High-molecular-mass DNA was extracted by phenol:chloroform:isoamyl alcohol (25:24:1), precipitated by isopropanol, washed with 70% ethanol and resuspended in 100 μl of TE. PCR was performed using Ex Taq (Takara) and the 27Fmod primer (5’-AATGATACGGCGACCACCGAGATCTACACTCTTCTATGGGCTCAG-3′) and the 338R primer (5’-TCAGGGTTATCCTGTAGTGACCTG-3′) to the V1–V2 region of the 16S rRNA gene (where XXXXX represents the Miseq (Illumina) Index sequence). The PCR product was purified with Agencourt AMPure XP (Beckman Coulter) according to the manufacturer’s protocol. The 16S rRNA library was created using the Kapa library quantification Kit (Kapa Biosystems) according to the manufacturer’s protocol. 16S rRNA sequencing was conducted using the standard protocol of MiSeq Reagent kit v.3. The obtained 16S rRNA sequencing data were analysed as previously described48. UCLUST (https://www.drive5.com/) was used to construct OTUs. Taxonomy was assigned to each OTU by searching against the National Center For Biotechnology Information (NCBI) using the GLSEARCH program.

Gnotobiotic studies and quantification of faecal bacterial DNA

With the exception of Phascolarctobacterium faecium (3G4), isolated bacterial strains were incubated in EGEF in an anaerobic chamber at 37 °C for 1–2 days. P. faecium was incubated on Oxoid CM0619 agar plates supplemented with 80 mM succinic sodium for 2–3 days, and colonies were collected and resuspended in EGEF. Bacterial density was adjusted on the basis of optical density at 600 nm (OD₆₀₀ values) and mixtures of the cultured strains were administered into GF mice (150 μl per mouse, approximately 1–2 × 10⁶ colony-forming units (CFU) of total bacteria) by oral gavage. For quantification of faecal DNA of P. clara, P. merdae, B. unifornis, P. rodentium and P. muris, mouse faecal DNA was purified and qPCR was performed to amplify a sequence specific to respective bacterial 16S rRNA gene using the Thunderbird SYBR qPCR Mix (Toyobo) on the LightCycler 480 System (Roche). For quantification of faecal DNA of the WT or Δ00502 P. clara, qPCR was carried out to amplify a sequence specific to the 00502 gene (for the WT) or a sequence spanning the upstream and downstream fragment of the 00502 gene (for Δ00502). Standard curves were generated from serial dilutions of bacterial genomic DNA purified from in vitro bacterial cultures of the respective strains. For analyses of the total faecal bacterial DNA, a universal bacterial 16S rRNA gene primer pair was used49. A list of all of the primers used for faecal bacterial DNA quantification is provided in Supplementary Table 5.

Bacterial whole-genome sequencing

Genomic DNA was extracted from the isolated bacteria including the P. clara 1C4 strain and sheared to yield DNA fragments. Bacterial genome sequencing was performed using the whole-genome shotgun strategy supported by the PacBio Sequel and Illumina MiSeq sequencing platforms. The TruSeq DNA PCR-Free kit was used to prepare the library of the Illumina MiSeq 2 × 300 bp paired-end sequencing with target length of 550 bp, and the FASTX toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) was used to trim and filter all of the MiSeq reads with a >20 quality value. The SMRTbell template prep kit 2.0 was used to generate the library of the PacBio Sequel sequencing with a target length of 10–15 kb without DNA shearing. Error correction of the trimmed reads was conducted by Canu (v.1.8) with additional options (corOutCoverage = 10,000, corMinCoverage = 0, corMhapSensitivity = high) after internal control removal and adapter trimming by Sequel. De novo hybrid assembly of the filter-passed MiSeq reads and the corrected Sequel reads was performed by Unicycler (v.0.4.8), including a check of overlapping and circularization, and a circular contig was generated. The Rapid Annotations based on Subsystem Technology (RAST) server and Prokka software tool were used for gene prediction and annotation of the generated contig. The default parameters were used for all software unless specified otherwise.

C. rodentium vaccination and infection

GF mice were pre-inoculated with 200 μl of 2-mix (B. uniformis 3H3 and P. merdae 1D4) + WT or Δ00502 P. clara and maintained for 4 days. The mice were then orally administered peracetic-acid-inactivated C. rodentium (10¹⁰ per mouse) once per week for three weeks. After three weeks of immunization, the mice were infected with an overnight culture of C. rodentium (150 μl per mouse) by oral gavage and euthanized on day 14 after infection. Peracetic-acid-inactivated C. rodentium was generated as previously described50. In brief, overnight cultures of C. rodentium were collected by centrifugation (16,000g, 10 min) and resuspended at a density of 10¹⁰ per ml in sterile PBS. Peracetic
acid (240990, Sigma-Aldrich) was added to the bacterial suspension (final concentration, 0.4%) and incubated for 1 h at room temperature. After washing three times with sterile PBS, the final pellet was resuspended at a final concentration of 10^6 particles per ml in PBS and stored at 4 °C. The vaccine was tested before use by inoculating 100 μl of the inactivated vaccine into 200 ml LB medium and incubating overnight at 37 °C to ensure complete inactivation. For the CFU assay, caecal patches or caecal luminal contents were collected and homogenized in PBS, and serially diluted homogenates were plated on LB agar plates. CFUs were counted after overnight incubation at 37 °C under aerobic conditions. For ex vivo evaluation of C. rodentium-specific IgA, caecal contents were digested with aseptically obtained fecal sample in 125 μl PBS (pH 7.4) by pipetting up and down, followed by centrifugation at 4 °C for 10 min. 

The remaining tissue was washed with PBS by pipetting up and down, followed by passing through 70 μm cell strainers, and centrifuged at 300g for 3 min. Isolated crypts were embedded in Matrigel (Corning) and cultured with organoid growth medium, as follows: Advanced DMEM/F-12 (Gibco) supplemented with 10 mM HEPES, 2 mM GlutaMAX, 100 U ml^-1 penicillin, 100 μg ml^-1 streptomycin, 20% Afamin/Wnt3a CM (MBL), 50 ng ml^-1 mouse recombinant EGF (Gibco), 100 ng ml^-1 mouse recombinant nogoig (Peprotech), 1 μg ml^-1 human recombinant R-spondin 1 (R&D Systems), 500 nM A83-01 (Tocris), 1× N2 supplement (Gibco), 1× B-27 supplement (Gibco) and 1 mM N-acetyl-L-cysteine (Sigma-Aldrich). The organoids were passaged mechanically every 4–5 days.

Before MHV-2 infection, organoids and MDCK cells (ATCC, CCL-34, mycoplasma-free) were dissociated into single cells using TrypLE express. A total of 2 × 10^6 cells was infected at a multiplicity of infection of 1 for 2 h at 37 °C under 5% CO₂ in the presence or absence of 1 μg ml^-1 bovine trypsin that was treated with L-1-tosylamido-2-phenyl ethyl chloromethyl ketone to inhibit contaminating chymotrypsin activity without affecting trypsin activity (Thermo Fisher Scientific). After infection, cells were washed twice with DMEM/F-12, embedded in Matrigel in a 48-well tissue culture plate and cultured in organoid growth medium at 37 °C with 5% CO₂. Each well contained 2 × 10^6 cells. At 24 h after plating, the samples were collected and suspended in DNA/RNA shield. The viral RNA copy number was determined as described above.

### In vitro degradation of trypsin

Overnight bacterial cultures were incubated with recombinant mouse trypsin (final concentration 1 μg ml^-1) for 1 h or human trypsin (final concentration 20 μg ml^-1) for 4 h. The recombinant trypsin isoforms used in this study were as follows: mouse recombinant PRSS2 (30383-M08H, Sino Biological), human recombinant PRSS1 (LS-G135640), human recombinant PRSS2 (LS-G20167) and human recombinant PRSS3 (His-tag) (NP112-52200). In some experiments, recombinant mouse PRSS2 was first treated with one of the following trypsin inhibitors for 30 min before incubation with P. clara: AEBFS (Sigma-Aldrich; final concentration, 2 mM), Leupeptin (Sigma-Aldrich; final concentration, 100 μM) and TLCK (Acbam; final concentration, 100 μM). In some of the experiments P. clara was grown overnight in the presence of tunicamycin (Sigma-Aldrich; final concentration, 10 μg ml^-1), 2-fluoro-1-fucose (Cayman Chemical; final concentration, 250 μM) or DMSO control before incubation with recombinant mouse PRSS2. For the experiments assessing the effect of Ca²⁺, P. clara was grown in a low-Ca²⁺ medium with or without supplementation with 1 mM CaCl₂ before incubation with mouse recombinant PRSS2. For experiments using P. clara supernatant, the P. clara overnight culture was filtered with a sterile filter unit with a PVDF membrane (0.22 μm pore size).

### Confocal microscopy

Recombinant mouse PRSS2 was labelled with Alexa Fluor 488 using Alexa Fluor 488 Antibody Labeling Kit (A20418, Thermo Fisher Scientific) and pretreated with AEBFS inhibitor (150 μg ml^-1) before incubation with P. clara (Sigma-Aldrich; final concentration, 2 mM). Leupeptin (Sigma-Aldrich; final concentration, 100 μM) and TLCK (Acbam; final concentration, 100 μM). In some of the experiments P. clara was grown overnight in the presence of tunicamycin (Sigma-Aldrich; final concentration, 10 μg ml^-1), 2-fluoro-1-fucose (Cayman Chemical; final concentration, 250 μM) or DMSO control before incubation with recombinant mouse PRSS2. For the experiments assessing the effect of Ca²⁺, P. clara was grown in a low-Ca²⁺ medium with or without supplementation with 1 mM CaCl₂ before incubation with mouse recombinant PRSS2. For experiments using P. clara supernatant, the P. clara overnight culture was filtered with a sterile filter unit with a PVDF membrane (0.22 μm pore size).

### Organoid culture and MHV-2 infection

Mouse small intestine and colon organoids were established as previously described. In brief, intestine tissues were opened longitudinally, washed with ice-cold PBS, cut into small pieces and subsequently treated with 5 mM EDTA on a rocking shaker for 30 min at 4 °C. After the supernatant was carefully removed, the remaining tissue was washed with PBS by pipetting up and down, followed by passed through 70 μm cell strainers, and centrifuged at 300g for 3 min. Isolated crypts were embedded in Matrigel (Corning) and cultured with organoid growth medium, as follows: Advanced DMEM/F-12 (Gibco) supplemented with 10 mM HEPES, 2 mM GlutaMAX, 100 U ml^-1 penicillin, 100 μg ml^-1 streptomycin, 20% Afamin/Wnt3a CM (MBL), 50 ng ml^-1 mouse recombinant EGF (Gibco), 100 ng ml^-1 mouse recombinant nogoig (Peprotech), 1 μg ml^-1 human recombinant R-spondin 1 (R&D Systems), 500 nM A83-01 (Tocris), 1× N2 supplement (Gibco), 1× B-27 supplement (Gibco) and 1 mM N-acetyl-L-cysteine (Sigma-Aldrich). The organoids were passaged mechanically every 4–5 days.

Before MHV-2 infection, organoids and MDCK cells (ATCC, CCL-34, mycoplasma-free) were dissociated into single cells using TrypLE express. A total of 2 × 10^6 cells was infected at a multiplicity of infection of 1 for 2 h at 37 °C under 5% CO₂ in the presence or absence of 1 μg ml^-1 bovine trypsin that was treated with L-1-tosylamido-2-phenyl ethyl chloromethyl ketone to inhibit contaminating chymotrypsin activity without affecting trypsin activity (Thermo Fisher Scientific). After infection, cells were washed twice with DMEM/F-12, embedded in Matrigel in a 48-well tissue culture plate and cultured in organoid growth medium at 37 °C with 5% CO₂. Each well contained 2 × 10^6 cells. At 24 h after plating, the samples were collected and suspended in DNA/RNA shield. The viral RNA copy number was determined as described above.
Protein staining of whole-cell lysate, supernatant and glycan-containing proteins

*P. clara* 1C4 was cultured overnight in the presence of Tunicamycin (Sigma-Aldrich; final concentration, 10 μg ml⁻¹), 2-fluro-l-fucose (Cayman Chemical; final concentration, 250 μM) or DMSO control. Cultured bacteria were then pelleted, washed once with PBS and lysed with 1% SDS solution (in 50 mM Tris-Cl buffer supplemented with 5 mM EDTA). SDS–PAGE was conducted using the Novex NuPAGE SDS–PAGE Gel system (Thermo Fisher Scientific). Glycan-containing proteins were stained with the Pro-Q Emerald 300 Glycoprotein Gel and Blot Stain Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. The protein contents of the whole-cell lysates were stained using the Colloidal Blue Staining kit (Thermo Fisher Scientific) according to the manufacturer's protocol. Supernatant was stained with 0.05 M PBS, the sections were stained with 12 nm Colloidal Gold antibodies (A190-214A, Bethyl laboratories) for 60 min. After washing again with 0.05 M PBS, the sections were fixed with 1% glutaraldehyde in 0.05 M PBS, washed with H2O and stained with uranyl acetate for 5 min. All of the images were taken using the JEOL JEM-1400 transmission electron microscope.

**Mutant generation**

The deletion mutants (Δ03049-03053, Δ00502 and Δ00509) of *P. clara* JCM14589 strains were incubated with mouse PRSS2 (final concentration 3 μg ml⁻¹), AEBSF-pretreated Alexa Fluor 488-labelled recombinant mouse PRSS2 (final concentration 5 μg ml⁻¹) or 50 μl GF caecal contents (50-fold dilution in PBS). For blue native gel electrophoresis, recombinant 00502 and 00509 were purified with anion-exchange and nickel-affinity chromatography and mixed with recombinant mouse PRSS2 (final concentration 3 μg ml⁻¹). AEBSF-pretreated Alexa Fluor 488-labelled recombinant mouse PRSS2 (final concentration 5 μg ml⁻¹) or 50 μl GF caecal contents (50-fold dilution in PBS). Blue native gel electrophoresis was used to determine the protease activity of the recombinant PRSS2. For blue native gel electrophoresis, recombinant human PRSS2 was pretreated with 20 mM AEBSF trypsin inhibitor for 30 min, incubated with 00502 (100 μg ml⁻¹) and then loaded to native PAGE gels. SERVAvNativ Marker Liquid Mix (SERVA, 39219) was used as the protein standard. For western blot analysis of blue native gels, proteins were blotted using the iBlot 2 Dry Blotting System with PVDF membranes (Thermo Fisher Scientific). A list of the primers used for the generation of the recombinants is provided in Supplementary Table 5.

**Protease activity assay**

The Pierce Fluorescent Protease Assay Kit (Thermo Fisher Scientific, 23266) was used to determine the protease activity of the *P. clara* culture, the *P. clara* culture supernatant, and recombinant 00502 and 00509 according to the manufacturer’s protocol. The PerkinElmer 2030 Multilabel Reader with fluorescein excitation and emission filters (485/538 nm) was used to detect increased total fluorescence as the fluorescein isothiocyanate (FITC)–casein substrate was digested by proteases into smaller fluorescein-labelled fragments. Protease activity was expressed as change in relative fluorescence units (RFU).

**Ex vivo degradation of IgA by faecal and recombinant trypsin**

Faeces from the 2-mix+WT *P. clara*-colonized mice and GF mice was incubated at 37 °C for 24 h. Alternatively, filtered and diluted (100-fold in PBS) faeces from the 2-mix+WT *P. clara*-colonized mice was incubated at 37 °C for 24 h with different concentrations of recombinant mouse PRSS2 (0–16 μg ml⁻¹) and then loaded to native PAGE gels. SERVAvNativ Marker Liquid Mix (SERVA, 39219) was used as the protein standard. For western blot analysis of blue native gels, proteins were blotted using the iBlot 2 Dry Blotting System with PVDF membranes (Thermo Fisher Scientific). A list of the primers used for the generation of the recombinants is provided in Supplementary Table 5.
protein contents of the samples were analysed using a trypsin-activity assay and western blotting as described above.

**Metagenomic analysis of the human gut microbiome**

Metagenomes from human faecal samples from PRISM\(^2\), HMP\(^3\), FHS\(^6\), 500FG\(^4\), CVON\(^5\) and jie\(^6\) were de novo assembled into a non-redundant gene catalogue, compiled into metagenomic species using M50miner\(^7\) and quantified in terms of relative abundance in a previous study\(^8\).

To search in the gene catalogue for the homologues of *P. clara* and *P. xylanphil*a genes from the trypsin-associated locus containing the genes 00502 and 00509, as well as six other neighbouring genes, we used USEARCH\(^8\) UPLAST (at protein level) retaining hits with a minimum e-value of 0.1. We confirmed the presence of all 9 genes in both species in the gene catalogue. To identify additional plausible homologues and species encoding this locus, we first evaluated the similarity between the corresponding homologues in *P. clara* and *P. xylanphil*a, and then the following thresholds of minimal identity (Id) and coverage (Cov) for UPLAST hits to each gene in the locus: 00502, Id = 25%, Cov = 90%; 00503, Id = 70%, Cov = 90%; 00504, Id = 60%, Cov = 90%; 00505, Id = 60%, Cov = 90%; 00506, Id = 50%, Cov = 90%; 00507, Id = 25%, Cov = 90%; 00508, Id = 45%, Cov = 80%; 00509, Id = 20%, Cov = 30%.

We then evaluated which other metagenomic species encoded homologues of *P. clara* and *P. xylanphil*a 00502-00509, identifying MSP 0355 and MSP 0303. Although MSP 0355 and MSP 0303 were previously annotated to only the phylum Bacteroidetes\(^8\), we used UPLAST to compare their proteomes to the unified human gastrointestinal genome (UHGG) collection\(^9\). In both cases, most of the genes (>90%) mapped with high confidence (median amino acid identity >99% and e < 1 × 10^{-144}) to a single species representative in UHGG, annotating MSP 0355 and MSP 0303 as GUT_GENOME140082 and GUT_GENOME016875, respectively; in UHGG\(^9\), both were phylogenetically classified as Paraprevotella spp.

Moreover, we identified five M50ps that encoded homologues of 00502 and 00509: MSP 0081, MSP 0224, MSP 0288, MSP 0410 and MSP 0435. To evaluate which individuals in the COVID-19 cohort (described below) carried *P. clara*’s gene 00502 or its homologues, we quality controlled faecal metagenomic data using Trim_Galore\(^\text{!}\) to detect and remove sequencing adapters (minimum overlap of 5 bp) and KneadData v.0.7.2 to remove human DNA contamination and trim low-quality sequences (HEADCROP:15, SLIDINGWINDOW:1:20), and retained reads that were at least 50 bp long. Paired-end quality-filtered reads were mapped to the same gene catalogue from a previous study\(^8\) with BWA\(^8\), filtered to include strong mappings with at least 95% sequence identity over the length of the read, counted and normalized to transcripts per million (TPM matrix).

Detection (TPM > 0) of any of the 00502 homologues classified the sample as containing a 00502 gene in their gut microbiome. All of the metagenomic samples in the COVID-19 cohort had at least 8 million reads after quality filtering.

**AlphaFold modelling**

The amino acids sequences of 00502 from *P. clara* and *P. xylanphil*a, and the 16S rRNA sequence data (accession code: DRA014249) and the 16S rRNA sequence data (accession code: DRA013874) are deposited in the DNA Data Bank of Japan. Metagenomic data of the COVID-19 cohort are deposited in NCBI under BioProject PRJNA821123. Proteinomes and peptidomics data are deposited in the ProteomeXchange Consortium via the JPOST partner repository (ID: PXD025768 and PXD032242).

Publicly available datasets of the mouse proteome database (https://www.uniprot.org/proteomes/UP000000589) and human PRSS2 protein sequence (https://www.uniprot.org/uniprotkb/P07478/entry) were used in this study. Source data are provided with this paper.

**Code availability**

No code was developed for this analysis.

40. Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. *Nature* **565**, 600–605 (2019).
41. Amodio, D. et al. Improving precursor selectivity in data-independent acquisition using overlapping windows. *J. Am. Soc. Mass. Spectrom.* **30**, 669–684 (2019).
42. MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. *Bioinformatics* **26**, 966–968 (2010).
43. Gessulat, S. et al. ProSist: proteome-wide prediction of peptide tandem mass spectra by deep learning. *Nat. Methods* **16**, 509–518 (2019).
44. Searle, B. C. et al. Generating high quality libraries for DIA MS with empirically corrected peptide predictions. *Nat. Commun.* **11**, 5548 (2020).
45. Searle, B. C. et al. Chromatogram libraries improve peptide detection and quantification by data independent acquisition mass spectrometry. *Nat. Commun.* **9**, 5128 (2018).
46. Kawashima, Y. et al. High-yield peptide-extraction method for the discovery of subnanobol markers from small serum samples. J. Proteome Res. 9, 1694–1705 (2010).
47. Konno, R. et al. Highly accurate and precise quantification strategy using stable isotope dimethyl labeling coupled with GeLC-MS/MS. Biochem. Biophys. Res. Commun. 550, 37–42 (2021).
48. Nishijima, S. et al. The gut microbiome of healthy Japanese and its microbial and functional uniqueness. DNA Res. 23, 125–133 (2016).
49. Atarashi, K. et al. Th1 cell induction by adhesion of microbes to intestinal epithelial cells. Cell 163, 367–380 (2015).
50. Sugimoto, S. et al. Reconstruction of the human colon epithelium in vivo. Cell Stem Cell 22, 171–176 (2018).
51. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762–1772 (2011).
52. Franzosa, E. A. et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease. Nat. Microbiol. 4, 293–305 (2019).
53. Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655–662 (2019).
54. Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136. e1128 (2016).
55. Kurilshikov, A. et al. Gut microbial associations to plasma metabolites linked to cardiovascular phenotypes and risk: a cross-sectional study. Circ. Res. 124, 1808–1820 (2019).
56. Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017).
57. Plaza-Oñate, F. et al. MSPrimer: abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data. Bioinformatics 35, 1544–1552 (2019).
58. Edgar, R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
59. Almeida, A. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat. Biotechnol. 39, 105–114 (2020).
60. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
61. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
62. Mindita, M. et al. ColabFold: making protein-folding accessible to all. Nat. Methods 19, 679–682 (2022).
63. Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
64. Namkung, H. et al. DOCK2 is involved in the host genetics and biology of severe COVID-19. Nature https://doi.org/10.1038/s41586-022-05163-5 (2022).
65. González-Dominguez, J. & Schmidt, B. ParDRe: faster parallel duplicated reads removal tool for sequencing studies. Bioinformatics 32, 1562–1564 (2016).
66. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastsp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884–i890 (2018).
67. Li, H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34, 3094–3100 (2018).

Acknowledgements We thank P. D. Burrows for comments; S. Narushima, T. Tanoue, T. Tanaka, S. Saegusa, M. Takekawa and M. Kumamoto for technical support and advice; H. Ikei and T. Matsu for coordinating and performing transmission electron microscopy experiments, and all of the staff members who supported us in the Keio University Hospital clinical COVID-19 Team, Keio Denen Project Team and the Japan COVID-19 Task Force. K.H. is funded through Japan Agency for Medical Research and Development (AMED) Project “The next-generation drug discovery and development technology on regulating intestinal microbiome (NeDD Trim)” (JP21be012014). AMED COVID-19-related R&D project under grant number JP20he062002, AMED LEAP under grant number JP20gm00100003, Grant-in-Aid for Specially Promoted Research from JSPS (no. 20H05627) and Stand Up To Cancer (SU2C) Convergence 3.416 Grant. D.R.P. and R.J.X. were funded by Center for the Study of Inflammatory Bowel Disease (DK043351) and AT006708 Y.L. received funding from RIKEN's SPDR programme and the European Union's Horizon 2020 Research and Innovation programme under the Marie Skłodowska-Curie Actions Grant, agreement no. 80113 (Scientia Fellowship). This study was also supported by AMED grants JP20fk0108452, JP20fk0108415, JP20nk010612 and JP20ek020154. E.W. acknowledges support from RIKEN's JRA programme.

Author contributions paper together with Y.K., D.R.P., R.W., R.J.X. and K.A., E.W. and Y.L. conducted bacterial and animal experiments supported by Z.W., K.N., K.A., S.S., T.M., X.Z. and K.W., Y.L. devised and performed the mechanistic studies. Y.K. and O.O. conducted proteome and peptide analyses. R.W. and K.Y. conducted structural predictions. J.F., J.M.N., B.O. and S.M. provided essential materials. K.A. and M.U. performed MHV-2 experiments. D.R.P., Q.Y.A., S.M.K., W.S., M.H. and R.J.X. performed microbiome and bioinformatic analysis. K.A., M.F., K.T., N.H., Y.U., M.I., K.F. and N.H. contributed to the Keio COVID-19 cohort analyses.

Competing interests K.H. is a scientific advisory board member of Vedanta Biosciences and 4BIO CAPITAL. K.W. is an employee of JSR corporation. J.M.N. and B.O. are employees of Vedanta Biosciences. R.J.X. is co-founder of Celsius Therapeutics and Inna Therapeutics & SAB member, Senda Biosciences and Nestle. The other authors declare no competing interests.

Additional information Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-022-05161-3.

Correspondence and requests for materials should be addressed to Ramnik J. Xavier, Koji Atarashi or Kenya Honda.

Peer review information Nature thanks Daniel Ducida and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | Elevated trypsin levels in germ free (GF) mice, and in humans and mice with intestinal inflammation. Distribution of all host-derived proteins detected in the proteome analysis of the caecal contents from specific-pathogen-free (SPF) or GF mice, with protein relative abundance plotted against p value. Anionic trypsin 2 (PRSS2) is highlighted in red. See Supplementary Table 1 for the complete list of proteins detected. b, Faecal trypsin activity of healthy controls, ulcerative colitis (UC) and Crohn’s disease (CD) patients. c, Faecal trypsin activity of Il10+/- and Il10−/− mice. b, c, Data shown as mean ± s.d. Each dot represents one human subject or one mouse. ** p < 0.01; * p < 0.05. One-way ANOVA with Tukey’s test (b) and two-sided Mann-Whitney test with Welch’s correction (nonparametric) (c).
Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Reduced faecal trypsin levels in gnotobiotic mice colonized with bacterial mixtures containing P. clara. 

a, Schematic representation of the strategy for isolating trypsin-reducing bacteria from the healthy human gut microbiota. The caecal contents from a GF mouse colonized with the donor C microbiota and receiving ampicillin treatment were cultured anaerobically on various types of agar plates containing different growth media including EG, ES, M10, NBGT, VS, BL, BBE, Oxoid CM0619, CM0619-supplemented SR0107, CM0619-supplemented SR0108, mGAM and Schaedler. 432 bacterial colonies were picked and sequenced. The 35 strains identified were subjected to further rounds of gnotobiotic and in vitro screening until identification of P. clara as the effector strain. 

b, Spearman’s correlation coefficient quantifying the association between relative abundance and trypsin activity for individual bacterial OTUs detected in mice in Fig. 2a. Operational taxonomic units (OTUs) significantly negatively correlated ($\rho \leq -0.5$, $p < 0.05$), negatively but not significantly correlated, and positively correlated with trypsin activity are marked in red, grey and blue, respectively. 

c, Western Blot analysis of mouse trypsin (PRSS2) in the faeces from GF mice colonized with the indicated bacterial mixtures. Images from one experiment are shown. See Supplementary Figure 1 for blot source data.
**Extended Data Fig. 3** See next page for caption.
Extended Data Fig. 3 | Initial mechanistic studies of Paraprevotella-mediated trypsin degradation. a, GF mouse caecal contents were incubated with *P. clara* 1C4 [*P. clara* (+)] or medium control [*P. clara* (−)]. Supernatant samples were collected at the indicated time points and subjected to peptidome analysis. Changes in levels of peptides derived from representative mouse proteins are shown. See Supplementary Table 2 for the complete list of peptides detected. b, c, GF mouse caecal contents (contain high levels of trypsin) were incubated with *P. clara* 1C4 [*P. clara* (+)] or medium control [*P. clara* (−)]. Trypsin (PRSS2) levels were analysed by Western Blot (b) or by trypsin activity assay (c) at the indicated time points. d, His-tagged recombinant mouse trypsin (rmPRSS2) was incubated with *P. clara* 1C4 cultured in a low-calcium medium (mGAM) or in mGAM supplemented with 1mM Ca²⁺ and degradation of rmPRSS2 was analysed by Western Blot with anti-His tag antibody. e, rmPRSS2 was incubated with *P. clara* 1C4 or filtered *P. clara* 1C4 supernatant, and degradation of rmPRSS2 was analysed by Western Blot with anti-His tag antibody. f, Protease activity of overnight live *P. clara* 1C4 culture or filtered *P. clara* 1C4 supernatant as determined by cleavage of FITC-labelled casein. Trypsin (1 ng μl⁻¹) was used as the positive control. Protease activity was expressed as change in relative fluorescence units (RFU). g, *P. clara* 1C4 was incubated with rmPRSS2 and then treated with disuccinimidyl sulfoxide (DSSO) cross-linker. The cross-linked interaction complex between rmPRSS2 and *P. clara*-derived molecules was analysed by Western blot with anti-His tag antibody. *P. clara* 1C4 without incubation with rmPRSS2 (*P. clara* 1C4 only) was used as the negative control. b, d, e, g, Representative images from two (d, e) or three (g) independent experiments with similar results, or an image from one experiment (b) are shown. See Supplementary Figure 1 for blot source data.
Extended Data Fig. 4 | Shedding of *Paraprevotella* proteins into the supernatant following treatment with tunicamycin. a, b, *P. clara* 1C4 was pre-treated with 2F-Fuc [2F-Fuc (+)] or vehicle control [2F-Fuc (−)] followed by incubation with rmPRSS2. Association of rmPRSS2 with *P. clara* 1C4 was examined by confocal microscopy (a) and degradation of rmPRSS2 was analysed by Western Blot with anti-His-tag antibody (b). Scale bar: 5 μm (a). c, *P. clara* 1C4 was treated with tunicamycin or vehicle control, and whole cell lysates were analysed for protein (left) and glycan (right) contents with Colloidal Coomassie Blue staining and Pro-Q Emerald 300 staining, respectively. d, Supernatant proteins from samples in (c) were analysed with Colloidal Coomassie Blue staining. Arrowheads indicate the bands that were decreased (c) or increased (d) after tunicamycin treatment. a–d, Representative images from two independent experiments with similar results are shown. See Supplementary Figure 1 for gel and blot source data.
Extended Data Fig. 5 | Type IX secretion system (T9SS) components in Paraprevotella genomes and generation of insertional mutants for P. clara JCM14859. **a**, Alignment of T9SS gene components in the genomes of P. clara JCM14859, P. xylaniphila JCM14860 and P. gingivalis ATCC 33277. **b**, Schematic illustration of insertional mutagenesis by plasmid integration. PCR validation results for the indicated mutants are shown. Primers used for mutagenesis and PCR validation are listed in Supplementary Table 5. pLGB30: suicide vector used for cloning and integrating sequences into P. clara JCM14859. **b**, Images from one experiment are shown. See Supplementary Figure 1 for gel source data.
**Article**

### Figure 6

![Diagram](image)

### Extended Data Fig. 6

See next page for caption.
Extended Data Fig. 6 | Generation of gene deletion mutants of *P. clara* JCM14859, growth of mutants deficient in trypsin degradation and analysis of genes located between 00502 and 00509. a, Schematic illustration (upper panel) and PCR validation (lower panels) of 00502-03003, 00502 and 00509 gene deletion. Primers used for mutagenesis and PCR validation are listed in Supplementary Table S. pLGB30: suicide vector used for cloning and integrating sequences into *P. clara* JCM14859. b, Wild type (WT), Δ00502 or Δ00509 *P. clara* JCM14859 strains were incubated with recombinant mouse PRSS2 (rmPRSS2) and degradation of rmPRSS2 was analysed by Western Blot with anti-His tag antibody. c, *In vitro* growth rate of mutants deficient in trypsin degradation as determined by OD600. : d, Alignment of the 00502-00509 gene cluster in *Paraprevotella* genomes and annotation of each protein with Prokka 1.14.6. e, Wild type (WT) or the indicated mutant strains of *P. clara* JCM14589 were incubated with rmPRSS2, and degradation of rmPRSS2 was analysed by Western Blot. Data shown as mean ± s.d. *n* = 5 wells of individual bacterial cultures per group. a, b, e, Images from one experiment are shown. See Supplementary Figure 1 for gel and blot source data.
**Extended Data Fig. 7** See next page for caption.
Extended Data Fig. 7 | Generation of recombinant PROKKA_00502 (r00502) and PROKKA_00509 (r00509), and assessment of their trypsin-binding and -degrading properties. **a, b**, *E. coli* hosts carrying expression vectors for r00502 or r00509 were treated with IPTG to induce recombinant protein expression (**a**), and the expressed r00502 or r00509 were purified from cell lysates (**b**). Protein contents of the whole cell lysates (‘Input’ and ‘Flow through’) or purified recombinants (‘Eluted’) were analysed with Coomassie Blue staining. Arrows indicate protein bands of r00502 or r00509 with the predicted molecular weights. **c**, Protease activity of r00502 or r00509 as determined by cleavage of FITC-labelled casein. Trypsin was used as the positive control. (-): no protein added. Protease activity was expressed as change in relative fluorescence units (RFU). **d**, Caecal contents from germ-free (GF) mice were incubated with medium control (-) or beads coupled with recombinant 00502 [00502 (beads)], and ex vivo degradation of trypsin was analysed by Western Blot at the indicated time points with anti-mouse PRSS2 antibody. * Cleaved fragments of PRSS2. **e**, SDS-PAGE (**left**) and Native PAGE (**right**) analysis of the purified r00502. Arrows indicate the monomer (1) and the possible oligomer form (2) of r00502 on a native PAGE gel. **f**, r00502 was incubated with recombinant human trypsin (hPRSS2, pretreated with trypsin inhibitor AEBSF) at the indicated concentrations at room temperature for 20 min, the reaction mix was analysed by a native PAGE and then subject to Coomassie Blue staining (**left**) or Western Blot analysis using antibodies against r00502 (anti-His-tag, **middle**) and hPRSS2 (**right**). Arrows indicate the bands corresponding to r00502 monomer (1), r00502 oligomer (2), r00502 monomer complexed with hPRSS2 (3) and r00502 oligomer complexed with hPRSS2 complex (4) that were excised for proteomic analysis (Supplementary Table 3). The marker used here is designed for SDS-PAGE-based chemiluminescent Western blot and does not reflect the actual molecular weight on a Native PAGE gel. It was used only for the purpose of alignment of the individual bands between the gel and the blots. **g**, Native PAGE analysis and Coomassie Blue staining of the recombinant proteins incubated alone or as mixtures at room temperature for 20 min. hPRSS2 was pre-treated with AEBSF to inhibit the trypsin activity. Arrows indicate the migration shifts of the r00502 bands when hPRSS2 was present. * degraded fragment of r00509 by hPRSS2. **a, b, d–g**, Representative images from two independent experiments with similar results are shown. See Supplementary Figure 1 for gel and blot source data.
Extended Data Fig. 8 | Model of *Paraprevotella*-mediated trypsin degradation and structural predictions of 00502. **a,** Model of *Paraprevotella*-mediated trypsin degradation: 00502 and 00509 proteins are transported across the outer membrane of *Paraprevotella* via the Type IX secretion system (T9SS). PorU is an essential T9SS component that cleaves the C-terminal domain (CTD) of T9SS-dependent proteins and anchors the proteins to *Paraprevotella* LPS molecules. WecA mediates the initial step of LPS O-glycan synthesis, and disruption of WecA function (e.g., with tunicamycin treatment) causes release of T9SS-dependent proteins. 00502 acts as a core effector component, facilitating trypsin association and auto-degradation possibly mediated by 00502 oligomerization, whereas 00509 may play a supporting and dispensable role in facilitating trypsin recruitment. Sec: Sec system that exports proteins across the cytoplasmic membrane. **b,** AlphaFold2-based structural prediction of *P. clara* 00502 protein with individual domains highlighted. Four out of the five Ig-like domains are shown; the last Ig-like domain that serves as the T9SS C-terminal target domain therefore does not form part of the Ig-like domain clustering zone is omitted here (shown separately in panel g). **c–f,** AlphaFold2-based structural prediction of *P. xylaniphila*, *P. rara*, *P. rodentium* and *P. muris* 00502 homologues with the conserved Ig-like domain clustering zone highlighted. **g,** Alignment of the C-terminal domain (CTD) of *P. clara* 00502 with that of *Porphyromonas gingivalis* RgpB protein. The "KXXXK" motif is a signature of T9SS C-terminal target domain-containing proteins.
Extended Data Fig. 9 | See next page for caption.
Extended Data Fig. 9 | Trypsin degradation confers *P. clara* a fitness advantage under competitive conditions. a–d, Germ-free (GF) mice were colonized with wild type (WT), ∆00502 or ∆00509 *P. clara* strains together with the 2-mix (*B. uniformis* 3H3 and *P. merdae* 1D4) (a & b, left panels, c), or colonized with WT or ∆00502 *P. clara* together with the 34-mix (a & b, right panels, d) for 14 days. n = 5 and 6 mice per group, respectively. Faecal *P. clara* DNA levels were determined by qPCR from a standard curve generated from serial dilutions of *P. clara* genome DNA (a). Fold change of total faecal bacterial DNA (relative to the average of the 2-mix+WT group and that of the 34-mix+WT group, respectively) was determined by a universal bacterial 16S rRNA gene primer pair (b). Faecal DNA of the 3 individual species was quantified by qPCR and their relative abundance was shown as percentage values (DNA of individual strain/total DNA of the 3 strains) (c). Relative abundance of the 35 individual bacterial species was analysed by 16s rRNA sequencing (d). e, Validation of the primers specifically amplifying genomic fragments from WT or ∆00502 *P. clara* strains for quantifying their abundance in (f, g). f, g, WT and ∆00502 *P. clara* strains were co-administered together with the 2-mix to GF mice. n = 7 mice. At the indicated days faecal DNA from each *P. clara* strain was quantified by qPCR. Both the absolute quantities (f) and the relative abundance (percentage of total *P. clara* DNA) (g) are shown. a, b, f, Data shown as mean ± s.d. ****p < 0.0001; **p < 0.01; n.s., not significant. One-way ANOVA with Tukey’s test (a & b, left panels), two-sided Mann-Whitney test with Welch’s correction (nonparametric) (a & b, right panels), and two-sided multiple unpaired t tests (not corrected for multiple comparisons) (f). Each dot represents one mouse (a, b, d). Two-sided multiple unpaired t tests (corrected for multiple comparisons using the Sidak-Bonferroni method); *** adjusted p value < 0.001. All primers used for faecal bacterial DNA quantification are listed in Supplementary Table 5. e, An image from one experiment is shown. See Supplementary Figure 1 for gel source data.
Extended Data Fig. 10 | See next page for caption.
**Extended Data Fig. 10 | Low trypsin levels enhanced the effectiveness of oral vaccines against *Citrobacter rodentium* in vivo and reduced MHV-2 infection in mouse intestinal organoids.**

**a.** Ex vivo degradation of IgA heavy chain by trypsin: faeces from the 2-mix+WT *P. clara*-colonized mice (2-mix+WT) and germ-free mice (GF) were diluted and filtered, incubated alone, mixed together (Mixture), or mixed in the presence of trypsin-specific inhibitor TLCK (Mixture+TLCK). Alternatively, faeces from the 2-mix+WT *P. clara*-colonized mice (2-mix+WT) were incubated with the indicated concentrations of recombinant mouse trypsin (rmPRSS2). After incubation at 37 °C for 24 h the indicated proteins were analysed by Western Blot (**left panel**), anti-mouse PRSS2 antibody was used to detect both faecal and recombinant mouse PRSS2. **Right panel:** trypsin activity of the loaded samples (**left panel**).

**b.** Schematic of the experimental setup for *C. rodentium* vaccination and infection (**c–f**). GF mice were inoculated with WT or Δ00502 *P. clara* JCM14859 strains (together with the 2-mix), orally vaccinated with peracetic acid-inactivated *C. rodentium* once per week for three weeks, followed by *C. rodentium* infection via oral gavage.

**c.** Changes in body weight of mice following *C. rodentium* infection.

**d.** Caecal patches and luminal contents were collected on day 14 post infection and analysed for *C. rodentium* CFU.

**e.** Western Blot analysis for the indicated proteins in the caecal luminal contents following *C. rodentium* vaccination and infection. * non-specific band. See Materials & Methods for detection of total and *C. rodentium*-specific IgA.

**f.** Agglutination effect of the filtered caecal suspension from 2-mix+WT *P. clara* and 2-mix+Δ00502 *P. clara*-colonized mice (following *C. rodentium* vaccination and infection), as demonstrated by incubation with an in vitro culture of live *C. rodentium*. **g.** Relative expression of transmembrane protease, serine 2 (TMPRSS2) and CEA cell adhesion molecule 1 (CEACAM1) in the organoids derived from mouse small intestine and colon was determined by RT-qPCR using β-Actin (ACTB) as the reference gene.

**h.** Colon organoids were infected with MHV-2 at MOI (multiplicity of infection) = 1 in the presence or absence of bovine trypsin for 2 h and washed with DMEM/F12 medium to remove uninfected virus. The viral RNA was quantified by RT-qPCR at 24 hrs post infection. MDCK cell line expressing the canine CEACAM1 with low homology to rodent CEACAM1 was used as the negative control. **c, d, n = 7 mice per group. Data shown as mean ± s.d. (c) and geometric mean ± geometric s.d. (d); ***p < 0.001; *p < 0.05; n.s., not significant. Two-sided multiple unpaired t-tests (not corrected for multiple comparisons) (e) and two-sided Mann-Whitney test with Welch’s correction (nonparametric) (d). Each dot represents one mouse (d). **g, h, n = 3 wells of cells per group. Each dot represents one well of cells. Data shown as mean ± s.d. *p < 0.05; n.s., not significant. Two-sided unpaired t test (parametric). N. D., not detected (h). Scale bar: 10 μm (f). **Representative images from two experiments with similar results (f), or images from one experiment (a) are shown. **e.** Images from one experiment including all the mice used in panel c are shown. See Supplementary Figure 1 for blot source data.
Extended Data Fig. 11 | See next page for caption.
Extended Data Fig. 11 | Detection of 00502-carrying species in human and mouse microbiome. a, Computational mining for genes homologous to \textit{P. clara} 00502-00509 and encoding species. Results of homology search with USEARCH ublast (protein level) against a non-redundant gut microbiome gene catalogue with 5,929,528 genes, constrained to hits with minimum e-value of 0.1. Two metagenomic species (MSPs) annotated to \textit{Paraprevotella} genus (MSP 0303 and MSP 0335) encoded all or almost all homologues to \textit{P. clara} genes 00502-00509. 5 MSPs annotated to \textit{Bacteroidetes} (MSP 0081, MSP 0224, MSP 0288, MSP 0410 and MSP 0435) encoded homologues to genes 00502 and 00509 but lacked homologues to genes 00503-00508. To arrive at these additional MSPs, we interrogated homology hits that showed levels of amino acid identity and coverage similar to that between \textit{P. clara} and \textit{P. xylanphila} homologues (see Methods) and were encoded by the same MSP. b, c, Relative abundance (b) and prevalence (c) of the 9 identified human 00502-carrying species across 3372 de novo assembled human gut metagenomes from USA [PRISM (n = 152), HMP2 (n = 1462), FHS (n = 618)], Netherlands [500FG (n = 468), CVON (n = 288)] and China [Jie (n = 384)]. In b, thick horizontal lines indicate the median; box boundaries indicate interquartile range (IQR); whiskers represent values within 1.5 x IQR of the first and third quartiles.
Extended Data Fig. 12 | Trypsin degradation by 00502-carrying species. 

**a**, Degradation of recombinant mouse trypsin (rmPRSS2) following *in vitro* incubation with the indicated bacterial strains. **b**, Quantification of faecal DNA from *Prevotella rodentium* and *Prevotella muris* in SPF mice reared at RIKEN’s facility by RT-qPCR. **c**, Alexa Fluor 488-labelled rmPRSS2 (green) was incubated with the indicated strains, and association of rmPRSS2 with the bacterial surface was examined by confocal microscopy. Scale bar: 5 μm (c). **b**, Data shown as geometric mean ± geometric s.d. *n* = 5 mice. DL, detection limit. N. D., not detected. **a**, A representative image from two independent experiments with similar results (a), or images from one experiment (c) are shown. See Supplementary Figure 1 for blot source data.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a  Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  *Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  *Give P values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Software and code

Policy information about: availability of computer code

Data collection

Light: Cycler 480 software version 1.5.1 was used for collecting qPCR data.
PerkinElmer 2030 Manager was used for collecting protease and trypsin activity data.

Data analysis

GraphPadPrism v8.0 and Excel for Mac version 16.16.27 (2012) were used for statistical analysis.

For proteome analysis of caecal contents, all shotgun-MS files were searched against the mouse UniProt reference proteome (Proteome ID UP000000589, reviewed, canonical, https://www.uniprot.org/proteomes/UP000000589) using ProteinPilot software v. 4.5 with the Paragon algorithm (Sciex) for protein identification. The identified proteins were quantified from SWATH MS data using PeakView v.2.2 (Sciex).

For proteome analysis of P. clara culture supernatant, an isolation width for MS2 was set to 4 m/z and overlapping window parameters in 500-780 m/z were used window placements optimized by Skyline. MS files were searched against a P. clara spectral library using Scaffold DIA (Proteome Software, Inc., Portland, OR). The spectral library was generated from P. clara protein sequence databases by Prost. Peptide quantification was calculated by EncyclopeDI A algorithm in Scaffold DIA.

For peptidome analysis of P. clara incubated caecal contents, MS files were searched against the mouse UniProt reference proteome (Proteome ID UP000000589, reviewed, canonical, https://www.uniprot.org/proteomes/UP000000589) by PEAKS Studio.

For In-gel digestion and LC-MS/MS analysis, MS files were searched against the P. clara protein sequence database with human PRSS2 sequence (https://www.uniprot.org/uniprotkb/P07478/entry) using PEAKS Studio.

Metagenomes from human stool samples from PRISM, HMP2, FHS, SOOG, CVON and Jie were de novo assembled into a non-redundant gene catalogue, compiled into metagenomic species using MSMiner. To search in the gene catalogue for the homologs of P. clara and P. xylaniphila genes from the trypsin associated locus containing genes 00502 and 00509, as well six other neighboring genes, we employed USEARCH 50 blast (at protein level) retaining hits with a minimum e-value of 0.1.

For 16s analysis, UCSC (https://www.drive5.com/) was used to construct OTUs. Taxonomy was assigned to each OTUs by search against the National Center for Biotechnology Information (NCBI) using the GLSEARCH program. Bacterial whole genome sequencing was prepared using TruSeq DNA PCR-Free kit, FASTX-toolkit v0.0.13, SMRTbell template prep kit 2.0, and Canu v1.4. Sequences were assembled using Unicycler v0.4.8 and annotated using the Rapid Annotations based on Subsystem Technology (RAST) Prokaryotic Genome Annotation Server and Prokka: rapid prokaryotic genome annotation software tool.
Bacterial genome sequencing was performed by the whole-genome shotgun strategy supported by PacBio Sequel and Illumina MiSeq sequencing platforms. TruSeq DNA PCR-Free kit was used to prepare the library of the Illumina MiSeq 2 x 300bp paired-end sequencing with target length = 550bp, and FASTX-toolkit (hannonlab.cshl.edu/fastx_toolkit) was used to trim and filter all the MiSeq reads with a >20 quality value (Q20). SMRTbell template prep kit 2.0 was used to generate the library of the PacBio Sequel sequencing with target length = 10 - 15kbp without DNA shearing. Error correction of the trimmed reads was conducted by Canu (v1.8) with additional options (kmerCoverage = 10,000, corMinCoverage = 0, corMinSensitivity = high) following internal control removal and adaptor trimming by Sequel. De novo hybrid assembly of the filter-passed MiSeq reads and the corrected Sequl read was performed by Unicycler (v0.4.8), including a check of overlapping and circularization, and a circular contig was generated. Rapid Annotations based on Subsystem Technology (RST) server and Prokka software tool were used for gene prediction and annotation of the generated contig. Default parameters were used for all software unless specified otherwise.

00502 models were predicted using AlphaFold2 through ColabFold—an online platform for protein folding. Model confidence was evaluated through pLDDT scores with a pLDDT > 90 considered as very high model confidence. The resulting AlphaFold models were then aligned in PyMOL (Schrödinger) and visualized in ChimeraX.

To evaluate which individuals in the COVID-19 cohort carried P. claidea’s gene 00502 or its homologues, we quality controlled stoichiometric metagenomic data using Trim_Galore! to detect and remove sequencing adapters (minimum overlap of 5 bp) and KneadData v0.7.2 to remove human DNA contamination and trim low-quality sequences (HEADCROP:15, SLIDINGWINDOW:1:20), and retained reads that were at least 50 bp long. Paired-end merged discovered reads were mapped to the same gene catalogue from a previous study with BWA, filtered to include strong mappings with at least 95% sequence identity over the length of the read, counted and normalized to transcript-per-million (TPM matrix). Detection (TPM>0) of any of the 00502 homologues classified the sample as containing a 00502 gene in their gut microbiome. All metagenomic samples in the COVID-19 cohort had at least 8 million reads after quality filtering.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet in the public domain, we strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The sequenced Paraprevotella genome (accession code: DRA014249) and the 16S RNA sequence data (accession code: DRA013874) are deposited in the DNA Data Bank of Japan. Metagenomic data of the COVID-19 cohort are deposited in NCBI under BioProject PRJNA822327. Proteomics and metabolomics data are deposited in the ProteomeXchange Consortium via the iPOST partner repository (ID: PXD0027678 and PXD0032242). Publicly available datasets of the mouse proteome database (https://www.uniprot.org/proteomes/UP000000589) and human PRSS2 protein sequence (https://www.uniprot.org/uniprot/kb/P07478/entry) were used in this study.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences

All studies must disclose on these points even when the disclosure is negative.

| Sample size | No statistical methods were used to predetermine sample size. For the human cohorts, no sample size calculation was conducted as we were not testing for end clinical outcomes nor testing any intervention. Sample sizes therefore represent the maximum number of samples we could obtain during the recruitment period. The number of animals studied per treatment group was based on our previous knowledge of the reproducibility, balancing statistical robustness and animal welfare. |
| Data exclusions | No data were excluded. |
| Replication | For all experiments involving animals or human subjects, except for the MHV experiments in Fig. 4d-f, data from a single experiment were shown with the number of mice/subject used in each experiment clearly indicated in the figure panels. For the MHV experiments Fig. 4d-f, pooled data from three independent experiments were presented. For all the remaining experiments (except for Fig. 4i, Extended data Fig. 2c, 3b, 5b, 6a, 6b, 6e, 9e, 10a, 12c, which were conducted once), reproducibility was verified by conducting the experiment at least twice, which yielded comparable results. Extended data Fig. 5b, 6a & 9e involve genotyping of the bacteria, the technique (PCR) is rudimentary and the results were conclusive with a single experiment. Whenever possible, hypotheses were verified by multiple types of experiments/data. For example, Fig. 3i (TEM data) was additionally validated by our Western (Extended data Fig. 6a) and confocal data (Fig. 3h); Extended data Fig. 2c (Western data) was additionally validated by trypsin activity assay (Fig. 2b-e, g); Extended data Fig. 6b (Western data) was additionally validated by the confocal data (Fig. 3h) and supported by the in vivo data (Fig. 4a, b); Extended data Fig. 6e (Western data) was further supported by Fig. 4j and Extended data 12a, c (P. rara, P. rodentium and P. muris do not carry genes 00503-00508 yet are capable of degrading trypsin). Western data in Fig. 10a (left panel) was validated by trypsin activity assay (Fig. 10a, right panel). Confocal data in Fig. 12c were additionally supported by the Western data (Fig. 2). Extended data Fig. 12a) |
Randomization For the human cohorts no random allocation was used as our study was observational and did not test any intervention. For animal studies, mice were randomized into separate cages upon arrival from the vendor. Sex-matched littermates were used and the experiments were designed to test a single variable.

Blinding For the human cohorts no blinding was performed as our study was observational and did not test any intervention. The remaining experiments were designed to test a single variable therefore blinding was not relevant.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|---------------------------------|---------|
| n/a                             | n/a     |
| ☑ Antibodies                    | ☑ ChIP-seq |
| ☑ Eukaryotic cell lines         | ☑ Flow cytometry |
| ☑ Palaeontology and archaeology | ☑ MRI-based neuroimaging |
| ☑ Animals and other organisms   |         |
| ☑ Human research participants   |         |
| ☑ Clinical data                 |         |
| ☑ Dual use research of concern  |         |

Antibodies

Antibodies used in this study are as follows: Rabbit anti-PRSS2 antibody (LSBio LS-C296077), Alexa 488-labelled goat anti-rabbit IgG (ThermoFisher Scientific #A11008), Rabbit anti-mouse PRSS2 (Cosmo Bio Co., Ltd, CPA, Japan, custom-made), Rabbit anti-mouse HSP90 antibody (#4877, clone C45GS, Cell Signaling TECHNOLOGY), Rabbit anti-human PRSS2 (LS-B15726, LSBio), Rabbit anti-human PRSS5 (LS-331381, LSBio), Rabbit anti-mouse TMPRSS2 (LS-C373022, LSBio, raised against a sequence at the protease domain), Rabbit anti-6-His Antibody (A190-214A, Bethyl laboratories, to probe His-tagged recombinant mouse PRSS2 [rmpRSS2] and human PRSS3 [HPRSS3]), Goat anti-mouse IgG alpha-chain (HRP) (ab97235, Abcam), Rat anti-mouse kappa-chain (HRP) (ab99632, Abcam), Rabbit anti-mouse CELA3b (OACD03205, Avvaysybio), Anti-rabbit IgG (HRP-linked Antibody) (#7074, Cell Signalling TECHNOLOGY), Rabbit anti-mouse Reg3beta (S1153-R005, Sino Biological), Rabbit anti-6-His Antibody (A190-214A, Bethyl laboratories) was used to probe rmpRSS2 throughout the study except in Fig. 3j, where rabbit anti-mouse PRSS2 (Cosmo Bio Co., Ltd, CPA, Japan, custom-made) was used to differentiate rmpRSS2 from recombinant 00502 and 00509 (also His-tagged).

Validation

All primary antibodies were carefully validated in house with the specific bands at the expected molecular weights confirmed. Rabbit anti-PRSS2 antibody (LSBio LS-C296077) was validated by Western blot using mouse faecal samples prior to its use for immunofluorescence. Rabbit anti-mouse PRSS2 (Cosmo Bio Co., Ltd, CPA, Japan, custom-made) was validated by Western blot using mouse faecal samples (Fig. 1c, 4b). Rabbit anti-mouse HSP90 antibody (#4877, clone C45GS, Cell Signaling TECHNOLOGY) was validated by Western blot using mouse pancreas lysates (Fig. 1f). Rabbit anti-human PRSS2 (LS-B15776, LSBio) and Rabbit anti-human PRSS5 (LS-331381, LSBio) were validated by Western blot using recombinant human PRSS2 and PRSS5, respectively (Fig. 2i). Rabbit anti-mouse TMPRSS2 (LS-C373022, LSBio, raised against a sequence at the protease domain), Goat anti-mouse IgA alpha-chain (HRP) (ab97235, Abcam), Rat anti-mouse kappa-chain (HRP) (ab99632, Abcam), Rabbit anti-mouse Reg3beta (S1153-R005, Sino Biological) and Rabbit anti-mouse CELA3b (OACD03205, Avvaysybio) were validated by Western using mouse faecal samples (Fig. 4b). Rabbit anti-6-His Antibody (A190-214A, Bethyl laboratories) was validated by Western using recombinant mouse PRSS2 and human PRSS3 (both His-tagged, Fig. 2f, i, j).

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) MDCK cell line from ATCC

Authentication The cell line was supplied and certified by ATCC and was immediately used for the experiment upon receipt to avoid any contamination.

Mycoplasma contamination The cell line was verified to be mycoplasma negative by the supplier.

Commonly misidentified lines (See LMSC registra) N/A

Animals and other organisms

Policy information about studies involving animals, ARRIVE guidelines recommended for reporting animal research

Laboratory animals CS7BL/6J mice maintained under SPF or germ-free conditions were purchased from Sankyo Laboratories Japan, SLC Japan, Charles River Japan or CLEA Japan. Gnotobiotic mice were maintained within the gnotobiotic facility of RIKEN IMS. 8-15 weeks old SPF and
germ-free WT male and female mice were used in this study. Sex-matched littersmates were used in all experiments. All animals were maintained on the 12-hour light-dark cycle and received gamma-irradiated (50 KGY) pellet food (CMF, Oriental Yeast). Temperature of 20-24°C and humidity 40-60% were used for the housing conditions.

**Wild animals**

The study did not involve wild animals.

**Field-collected samples**

The study did not involve samples collected from the field.

**Ethics oversight**

All animal experiments were approved by the Animal Care and Use Committee of RIKEN Yokohama Institute.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

---

**Human research participants**

Policy information about: studies involving human research participants

**Population characteristics**

This study used faecal samples from healthy human donors and IBD patients, as well as faecal samples from COVID-19 patients.

For healthy human donors, 41 participants were recruited. Age 23-56 yo (average 34.5 yo), 29 male and 12 female.

For the IBD patients, we used 39 subjects (5 CD patients & 34 UC patients). Age 17-78 yo (average 48.5 yo), 27 male & 12 female.

For the COVID-19 cohort, 146 patients were recruited. Age 17-79 yo (average age of 50.95 yo), 93 male and 53 female.

**Recruitment**

For the healthy control group, volunteers were recruited by posting information leaflets or e-mailing through institutional mailing lists of Keio University School of Medicine and RIKEN Yokohama Institute. Subjects (all Japanese residents) were eligible for the study if they were over the age of 20 and provided written, informed consent. Subjects were not eligible if they underwent antibiotic exposure in the previous month. We worked to ensure gender balance in the recruitment of human subjects.

For patients with IBD, we recruited patients (all Japanese) with gastrointestinal diseases or suspected gastrointestinal diseases who visited the Department of Gastroenterology of Osaka City University. Participants were informed about the significance and methods of the study prior to participation, and their consent to participate was obtained. The endoscopy was done to diagnose disease and assess disease activity. We worked to ensure gender balance in the recruitment of human subjects.

The COVID-19 cohort was recruited as a part of the Japan COVID-19 Task Force (ICTF) study. We recruited 146 patients who were diagnosed as COVID-19 by physicians using the clinical manifestation and PCR test results and hospitalized at Keio University Hospital from March 2020 to September 2021. Approximately two months after discharge from the hospital, faecal samples were collected and sent to the laboratory in DNA/RNA Shield (Zymo Research), following a protocol approved by the Institution Review Board of Keio University School of Medicine (code 20190337). Informed consent was obtained from each subject.

There was no bias towards selection of any particular group.

**Ethics oversight**

For collection of human faecal samples for gnotobiotic studies and for the comparison of faecal trypsin activity between IBD patients and healthy controls, human faecal samples were collected at RIKEN Institute (code H30-4, for patients with IBD) and Keio University (code 20150075, for healthy donors) according to the study protocols approved by the institutional review boards. Informed consent was obtained from each subject.

For the COVID-19 cohort, a protocol approved by the Institution Review Board of Keio University School of Medicine (code 20190337) was followed. Informed consent was obtained from each subject.

Note that full information on the approval of the study protocol must also be provided in the manuscript.